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ABSTRACT 
Mechanically-activated delivery systems harness existing physiological and/or 
externally-applied forces to provide spatiotemporal control over the release of active 
agents. The presence and necessity of these forces in the human body and in the 
increasing use of mechanically-driven medical devices (e.g., stents, balloon catheters, 
gastric bands, tissue expanders) can serve as functional dynamic triggers. Therefore, this 
dissertation investigates the use of applied tensile strain and cyclic loading to control 
release of entrapped agents, and further translates the concept towards clinical 
applications by integrating the system with commercial medical devices that provide 
precise forces to trigger release.  
As an initial proof-of-concept, mechanoresponsive composites, consisting of 
highly-textured superhydrophobic barrier coatings over a hydrophilic substrate, are 
fabricated. The release of entrapped agents, controlled by the magnitude of applied strain, 
results in a graded response due to water infiltration through propagating patterned cracks 
in the coating. The strain-dependent delivery of anticancer agents with in vitro efficacy as 
well as the ex vivo delivery to esophageal tissue with an integrated stent system are 
		 ix 
demonstrated.  
Release is further modulated by barrier coating properties. Thicker coatings afford 
slower release rates with preserved in vitro activity for both a chemotherapeutic and an 
enzyme. Localizing coating crack patterns based on different geometric stress 
concentration factors further controls the selective sequential release of multiple agents.  
Finally, the development of a reversible mechanoresponsive system is 
investigated to provide cycle-mediated pulsatile release. Optimization of mechanical 
parameters results in delivery of multiple doses. To translate this concept towards the 
clinic, the system is integrated with commercial balloon catheters to provide multidose 
delivery of small molecules to ex vivo vessels. Using the inherent inflation and deflation 
of the catheter to trigger release, the system enhances existing capabilities to treat 
cardiovascular and peripheral artery diseases.  
In summary, the development of mechanoresponsive systems that respond to 
tensile strain and cycle number are described for the delivery of a wide-range of active 
agents (hydrophilic and hydrophobic small molecules as well as an enzyme), and their 
integration with existing medical devices. Furthermore, the comprehensive range of 
specific kinetic profiles, including triggered release, pulsatile delivery, and the sequential 
delivery of multiple agents, showcases the capabilities and versatility of these dynamic 
mechanoresponsive systems to modulate release for the treatment of various clinical 
diseases. 
		 x 
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CHAPTER 1: Mechanoresponsive materials for drug delivery: Harnessing forces 
for controlled release 
Adapted from: Mechanoresponsive materials for drug delivery: Harnessing forces for 
controlled release. Advanced Drug Delivery Reviews. 2017; 108: 68-82.  
1.1 Abstract 
 Mechanically-activated delivery systems harness existing physiological and/or 
externally-applied forces to provide spatiotemporal control over the release of active 
agents. Current strategies to deliver therapeutic proteins and drugs use three types of 
mechanical stimuli: compression, tension, and shear. Based on the intended application, 
each stimulus requires specific material selection, in terms of substrate composition and 
size (e.g., macrostructured materials and nanomaterials), for optimal in vitro and in vivo 
performance. For example, compressive systems typically utilize hydrogels or 
elastomeric substrates that respond to and withstand cyclic compressive loading, whereas, 
tension-responsive systems use composites to compartmentalize payloads. Finally, shear-
activated systems are based on nanoassemblies or microaggregates that respond to 
physiological or externally-applied shear stresses. In order to provide a comprehensive 
assessment of current research on mechanoresponsive drug delivery, the mechanical 
stimuli intrinsically present in the human body are first discussed, along with the 
mechanical forces typically applied during medical device interventions, followed by in-
depth descriptions of compression, tension, and shear-mediated drug delivery devices. 
We conclude by summarizing the progress of current research aimed at integrating 
mechanoresponsive elements within these devices, identifying additional clinical 
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opportunities for mechanically-activated systems, and discussing future prospects. 
1.2 Introduction 
The delivery of therapeutic agents to a specific location with optimal dose and 
duration remains a significant clinical challenge. This multifaceted problem is being 
investigated using a myriad of drug delivery strategies because systemic drug 
administration—although widely used in the clinic—typically requires multiple doses to 
treat diseased tissue. However, this leads to significant and widespread off-target side 
effects due to exposure of healthy tissue. Stimuli-responsive materials are well-suited for 
applications in drug delivery, actively releasing their drug payloads in response to either 
physiological or externally-applied triggers. This spatiotemporal control over drug release 
is widely demonstrated for stimuli such as: pH,1–11 temperature,1,9,10,12–21 light,22–26 ionic 
strength,27–29 electrical potential,30–37 and applied magnetic fields.38–48 While some of 
these systems ultimately undergo a mechanical change, such as deformation, swelling, or 
change in modulus (i.e., when temperatures reach above the lower critical solution 
temperature or below the upper critical solution temperature), they will not be discussed 
as these systems are previously reviewed. Instead, this review highlights recent exciting 
breakthroughs with stimuli-responsive systems that respond directly to mechanical forces 
and summarizes pioneering reports that have launched the field. 
Mechanically-activated systems are triggered by mechanical forces in the body 
that either occur physiologically or are exerted on the body by external devices, both over 
a wide magnitude (Figure 1). Generally, an unopposed force exerted on an object 
accelerates its motion. The distribution of the force on the object is described as the 
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mechanical stress, which can result in deformation. Microscopic cellular forces49–54 are 
present and coordinate into macroscopic forces for processes such as wound repair and 
inflammation. Further coordination results in the exertion of even greater forces by 
various systems, such as the musculoskeletal,55,56 cardiovascular,57–59 and respiratory 
systems.60,61 Alternatively, external triggers are applied by medical devices such as 
stents62–65 and catheters66,67 that mechanically open blocked or narrowed structures, or are 
applied by another user or self-exerted to control administration. Therefore, drug and 
protein delivery systems that respond to mechanical forces serve as innovative solutions 
to control on-demand release within a physiological environment. Designing such 
mechanoresponsive systems that account for the dynamic nature of the human body will 
bring about novel solutions to clinical challenges. 
Mechanical stimuli are quantified by force and displacement (Figure 2). In 
compression, a force is applied, resulting in an equal but opposing force along the same 
axis, generally reducing the object’s length along that direction. Similarly, an object 
under tension is pulled or stretched, lengthening the object along the axis. This force, and 
resulting deformation, can be converted into stress and strain. For engineering stress (σ), 
the force is normalized by the cross sectional area while engineering strain (ε) calculates 
the relative change in displacement—the difference in length divided by the original 
length. Instead of applying forces normal to the cross section, shear forces are applied 
parallel to the object’s cross section. Shear stress is similarly defined as the parallel force 
divided by the cross sectional area acted upon; shear strain is the strain in the parallel 
direction. The overall elastic material property is expressed by Young’s modulus: E = 
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stress/ strain. The shear modulus is defined as G = E/ (2(1+ ν)), where ν is Poisson’s 
ratio, which describes the expansion of the material along the axis compared to the 
compression perpendicular to the axis. 
While there are relatively few reports of mechanoresponsive drug delivery 
systems,68 they cover the breadth of mechanical forces: compression, tension, and shear. 
Mechanoresponsive drug delivery is attractive due to the ease of applying compressive, 
tensile, and shear stimuli, and to the ubiquity of these forces in the human body. While 
ultrasound is also considered a mechanical stimulus, several recent reviews have been 
published on ultrasound-triggered drug delivery,69–83 and thus will not be discussed here. 
The scope of the current review focuses on drug delivery systems that utilize 
compression, tension, and shear, and are categorized according to the respective forces 
used for mechanical stimulation of drug release. 
1.3 Compressive-responsive systems 
Compressive delivery systems require substrates that respond to and withstand 
compressive loading. Commonly used materials for compression are elastomeric 
substrates. Elastomers are viscoelastic polymers—that is, they have viscous (resistance to 
flow) and elastic properties (tendency to return to its original shape after removal of 
stress) with time-dependent strain rate. Examples of elastomers in biomedical research 
include rubbers and silicones. As 3D-crosslinked polymer networks, hydrogels also 
withstand high compressive forces, and thus act as effective compressive systems. 
Examples of natural hydrogel polymers include alginate, chitosan, collagen, and 
hyaluronic acid, whereas examples of synthetic hydrogel polymers include 
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poly(hydroxyethylmethacrylate), polyacrylamides, poly(ethylene glycol), poly(vinyl 
alcohol), and poly(N-isopropyl acrylamide). Due to their biocompatibility and aqueous 
loading environment, hydrogels are widely used in the clinic and in biomedicine for 
tissue engineering,84–89 diagnostic,90–92 and drug and protein delivery93–98 applications. 
The availability of both types of substrates and the ability to apply compressive forces 
externally have led to numerous studies on controlling the release of drugs and proteins. 
1.3.1 Elastomeric deformation 
Elastomeric substrates possess the structural integrity required for compressive 
release. PY Wang reports one of the earliest successes of a user-controlled compressive 
system, where a two-compartment silicone implant releases insulin to reduce 
hyperglycemia in an in vivo diabetic rat model.99 The first compartment allows the influx 
of serous fluid to solubilize the insulin powder contained in the second compartment. 
Compression then drives the efflux of the insulin-dissolved serum. The author 
demonstrates efficacious insulin delivery from the implant in vivo using diabetic Wistar 
rats undergoing compressions (2 seconds followed by 1 minute massage) once a day, 
once every 2 days (Figure 3a), once every 3 days, and once every week, with subsequent 
reduction in blood sugar levels up to 28, 44, 72, and 140 days, respectively. Although the 
insulin ‘dose’ is similar in each case (i.e., reduction of blood glucose levels last for ~1 
day), the depletion rate increases with longer durations between administration; 
compressions once a day are effective over 28 stimulation events, while the device is 
only active for 20 stimulation events when compressed once a week. While the author 
addresses the retention of insulin bioactivity with this in vivo model, another concern is 
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the variability of forces used to compress the implants; better characterization of the 
forces exerted is necessary to control consistent delivery.  
Yang et al. describe another example of cyclical compressive release, 
demonstrating controlled release of bovine serum albumin (BSA) from porous 
matrices.100 In their study, BSA-loaded microspheres are incorporated within block 
copolymer poly(ethylene glycol)-b-poly(L-lactide) (PELA) scaffolds. Compression of the 
scaffolds (1 Hz) for 3 hours each day (4-5% compressive strain) for 30 days reveal 
accelerated BSA release from cyclic loading compared to the scaffold under static 
conditions. Half of the total BSA concentration releases after 4 days under cyclic loading 
while the release extends to 10 days under static conditions. This result is an 
improvement over BSA release from PELA microspheres without scaffolds, which 
release 50% of their payload after 2 days. The authors note areas for design improvement 
in their system including reducing the high degree of burst release from both static and 
compressed samples.  
In contrast to systems solely undergoing compression, Kim et al.101 recently 
report a microfabricated polydimethylsiloxane (PDMS) system, containing a 
microchannel adjacent to a refillable spherical reservoir, that is subjected to bending, 
which induces a range of compressive and tensile stresses and stress magnitudes. When 
the strain applied to the reservoir exceeds the critical strain (εc), or the strain at which the 
volume of the deformed reservoir exceeds the volume of the microchannel, the system 
releases compound due to strain-induced flow and diffusion (Figure 3b). Using 
rhodamine B as a model hydrophilic drug, the authors demonstrate control over delivery 
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kinetics, depending on the relative microchannel volume fraction (fch = Vch/VR x 100%) 
and bending radii (r = 19, 27, 45 mm). Without microchannels (fch = 0%), less inward 
bending (larger bending radius, r = 45 mm, Figure 3c) results in more on/off release 
profile and less release at each bending event (~2%), while more inward bending (smaller 
bending radius, r = 19 mm, Figure 3d) results in slow continuous diffusion in the absence 
of a bending trigger, with greater release at each bending event (~4%). Longer channels 
(up to fch = 9%) retain more buffer volume and therefore less rhodamine B releases with 
each bending event (for r = 19 mm, <0.5% releases at fch = 9% vs 4% release at fch = 0%) 
(Figure 3e). However, the maximal drug release is ≈70%, most likely attributed to the 
dead volume of the system, which the authors suggest can be solved by refilling the 
system with a syringe. 
Alternatively, Larsen et al. use a mechanochemical approach to activate the 
release of a furan-derivative through compression.102 The polyurethane-derived network 
crosslinked with oxanorbornadiene-based mechanophores undergoes orthogonal bonds 
breakage with mechanical compression via a retro-[4+2] cycloaddition reaction, resulting 
in the formation of an alkyl bond and release of the small molecule, benzyl furfuryl ether. 
The control system, consisting of physically but not chemically-incorporated 
mechanophores, has a baseline release of ~2%, regardless of the compressive pressure 
applied. In contrast, the mechanosensitive polyurethane network, containing the 
chemically incorporated mechanophores, shows increasing release from 1% to 6% with 
greater compression (up to 176 MPa). The authors also demonstrate compression-
triggered release of benzyl furfuryl ether with up to 9 consecutive cycles at 35 and 88 
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MPa for 1 minute (max ~7% activation). This mechanically-induced bond scission offers 
a chemical approach to release but limits the release to substrates containing furan 
functionalities with low release of the incorporated substrate. 
1.3.2 Hydrogel deformation 
Lee et al. report one of the earliest hydrogel compressive systems, composed of 
calcium crosslinked alginate, as a device to stimulate neovascularization through the 
delivery of physically entrapped vascular endothelial growth factor (VEGF).103,104 
Compression (six cycles with compression for 2 mins and relaxation for 8 mins between 
cycles) at 25% or 10% strain expedites the release rate of VEGF five-fold from the 
alginate hydrogel or two-fold, respectively, compared to the control (0% strain) (Figure 
4a). The authors also demonstrate the in vivo efficacy of these VEGF implants, showing 
nearly 7-fold greater tissue granulation and more than two-fold increase in blood vessel 
number in severe combined immunodeficient mice after 7 days of daily mechanical 
stimulation (three cycles with compression for 1 min followed by 1 min relaxation 
between cycles at 50% strain for 1 week), compared to unloaded hydrogels with and 
without mechanical stimulation. Similarly, in a non-obese diabetic mouse model, blood 
vessel density increases by 3-fold with VEGF hydrogels under mechanical stimulation 
(six cycles with compression for 30 seconds, followed by relaxation for 90 seconds, over 
1 week) compared to unloaded hydrogels with and without mechanical stimulation 
(Figures 4b and 4c). However, in the absence of compression, there is a non-zero release 
rate reported in vitro (~2 ng/ min) and a significantly higher amount of granulation and 
blood vessel number (or density) with non-mechanically stimulated VEGF-loaded 
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hydrogels (Figure 4b) compared to unloaded hydrogels. However, this passive release 
still results in significantly lower granulation and blood vessel density than mechanically-
stimulated VEGF-loaded hydrogels in both in vivo models.  
Extending the promising nature of alginate hydrogels for the delivery of 
hydrophobic compounds, β-cyclodextrin moieties increase drug loading and prolong 
release through host-guest interactions. β-cyclodextrin is a 7-membered sugar ring 
molecule with a hydrophobic center and hydrophilic sides. This, along with 21 hydroxyl 
groups available for modification, allows higher incorporation and better retention of 
hydrophobic drugs through van der Waals and hydrophobic complexes.105 Izawa et al. 
release ondansetron, a hydrophobic anti-emetic drug, from a compressive system of 
crosslinkable β-cyclodextrin grafted to alginate.106 Incorporation of the β-cyclodextrin 
moieties increase ondansetron binding to 170 M-1, compared to 25 M-1 for calcium-
crosslinked alginate gels. β-cyclodextrin-crosslinked alginate hydrogels are 
mechanically-responsive to compressive strain (50%, 30%, 0%) compared to β-
cyclodextrin-grafted hydrogels (single link to alginate) (Figure 4d), confirming the 
deformation of the β-cyclodextrin moiety, through its multi-connectivity with the alginate 
matrix, is required for mechanoresponsive release rather than enhanced diffusion by 
water exudation. 1-cycle compressions and 5-cycle compressions at 50% or 30% strains 
(5 mins compression followed by 5 mins relaxation) increases release over a 70-hour 
period (Figure 4e). The deformation due to compressive stimulus decreases ondansetron 
affinity to β-cyclodextrin by destabilizing the inclusion complex (50% strain decreases 
binding constant to 100 M-1 vs 170 M-1 with 0% strain). However, even with the 
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increased affinity of ondansetron, the system still passively releases half of the 
ondansetron over 18 hours with no mechanical stimulus (vs 7 hours at 50% strain, Figure 
4e).  
Similarly, Tan et al. report the use of β-cyclodextrin-conjugate alginate hydrogels, 
loaded with hydrocortisone acetate, an anti-inflammatory drug, as a potential wound 
healing implant.107 Calcium-crosslinked alginate gels (without mono-6-deoxy-6-
ethylenediamine-β-cyclodextrin (β-CD-EDA) grafts) are not mechanically responsive to 
3 kPa compressive stress—that is, mechanically stimulated and non-stimulated hydrogels 
release equally fast (50% release over ~5 hours). However, with increasing incorporation 
of β-CD-EDA (weight ratio from 50/0 to 27/23 alginate/ β-CD-EDA), mechanical 
sensitivity increases and release is prolonged as non-stimulated hydrogels release 50% 
over 30+ hours while stimulated hydrogels release in ~25 hours. In vitro studies in 
lipopolysaccharide-activated RAW264.7 murine macrophages demonstrate a nearly 8-
fold reduction of nitric oxide production over 72 hours, confirming the anti-inflammatory 
function of the hydrocortisone acetate from mechanically-stimulated hydrogels. 
However, the mechanical properties of the hydrogel need to be further optimized as there 
is a tradeoff with increasing β-CD-EDA concentration, which results in decreased overall 
mechanical strength of the system. For this reason, only one magnitude of compressive 
stress (3 kPa) is described (lower magnitudes would not be indicative of user-controlled 
compression). Moreover, the leakiness amongst all β-CD-EDA and alginate systems is a 
concern due to undesired drug release, similar to the previous two alginate systems. Thus, 
opportunities exist to improve mechanical properties and release mechanics as a future 
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user-controlled implant. 
Alternative compression-responsive systems composed of materials other than 
alginate are also reported. Xiao et al. use a hyaluronic acid (HA)-based hydrogel 
containing covalently integrated soft and deformable dexamethasone (DEX) micelles for 
pain management.108 The compressive release of anti-inflammatory drug DEX from 
hydrogel implants would relieve pain for osteoarthritic patients when degraded cartilage 
undergoes compression through daily activity. The hydrogel system consists of block 
copolymer micelles (BCM), composed of poly(acrylic acid-graft-2-hydroxyethyl 
acrylate)-block-poly(n-butyl acrylate) tethered to glycidyl methacrylate-modified HA 
using photo-initiated free-radical polymerization. Owing to its lipophilicity, DEX 
sequesters within the hydrophobic BCM cores, yet releases in an on-demand fashion 
through the application of compression (Figure 5a). With an hour of 30% compressive 
strain (12 cycles/hour), DEX releases at 345 µg/hour compared to 6 µg/hour under static 
conditions (Figure 5b); at 15% compressive strain (12 cycles/hour), DEX also releases 
but at a rate 1.6x slower compared to 30% strain (Figure 5b). However, a limitation of the 
system is the substantial burst release which requires a 3-hour washout period prior to 
performing experiments. Lastly, release of DEX from non-mechanically-stimulated 
hydrogels significantly reduces levels of secreted tumor necrosis factor α (and thus 
reduces RAW264.7 murine macrophage activation) after stimulation by 
lipopolysaccharide, demonstrating in vitro reduction of inflammation. 
Recently, Rajamanickam et al. release model drugs from elastic layer-by-layer 
microparticles (~17 µm) via cyclic compression.109 The alternating layers consist of 
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chitosan (Chi), alginate (Alg), or colloidal silica nanoparticles (SO2): (Chi-Alg-Chi)-
(Alg-Chi)3, (Chi-Alg-Chi)-(SO2-Chi)1, (Chi-Alg-Chi)-(SO2-Chi)3, or (Chi-Alg-Chi)-
(SO2-Chi)5. The chitosan layers are covalently crosslinked by glutaraldehyde at freezing 
temperatures to impart elasticity, while the colloidal silica nanoparticles reinforce the 
strength of the layers. Mechanical tests via capillary compression, capillary 
micromechanics, and osmotic pressure demonstrate that (Chi-Alg-Chi)-(SO2-Chi)3 
deform by more than 98% under compression with recovery, the shear modulus of the 
particles increases with greater deposition of SO2-Chi layers, and the critical osmotic 
pressure also increases with greater deposition of SO2-Chi layers. The microparticle 
assembly is capable of 30-40% diffusive loading of small and neutral dyes, such as 
fluorescein isothiocyanate (FITC) or FITC-dextran (4 kDa), but results in limited loading 
of polymeric and charged dyes. Nevertheless, FITC-dextran releases from a monolayer of 
(Chi-Alg-Chi)-(SO2-Chi)1 particles with 4 cyclic compression (0.98 N force for 6 
seconds, 12 min relaxation). With ~20% of the dye release at each cycle, the system with 
silica nanoparticles ((Chi-Alg-Chi)-(SO2-Chi)5) exhibits less burst release compared to 
the control ((Chi-Alg-Chi)-(Alg-Chi)3) (Figure 5c). Additionally, increasing the 
magnitude of force applied (4.9 N, 2.45 N, 0.98 N, Figure 5d) results in faster release 
while increasing the silica-chitosan layers (from (Chi-Alg-Chi)-(SO2-Chi)1 to (Chi-Alg-
Chi)-(SO2-Chi)3 and (Chi-Alg-Chi)-(SO2-Chi)5) decreases the release with each cycle 
(~15-20% dye released at each cycle) (Figure 5e). However, the authors do not 
demonstrate the activity of the released agents as the studies are conducted with model 
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compounds. Furthermore, how the particles would be compressed in vivo is not discussed 
as the experiments rely on a monolayer of immobilized particles. 
1.4 Tension-responsive systems 
Tension-responsive systems are an active area of study in the fields of sensors,110–
112 electronics,113–116 and more recently drug delivery. Each of these systems utilizes 
‘soft’ and often elastomeric materials. In drug and protein delivery, tension is an ideal 
stimulus because of the ubiquity of tension in the dynamic nature of the human body and 
the increasing use of tension-driven medical devices (i.e., stents, catheters).117  
While most hydrogels are capable of compressive loading, hydrogels often yield 
at low tensile strains (i.e., <50% strain).118 Zhang et al.119 can release horseradish 
peroxidase and Candida antarctica lipase B by stretching a interpenetrating alginate-
polyacrylamide hydrogel, first developed by Sun et al.120 Biaxial stretching increases the 
surface area of the hydrogel, allowing faster diffusion of substrate into the enzyme-
embedded hydrogel; an increase in surface area linearly correlates with activity of both 
enzymes. Heterogeneous composite systems, discussed in the following sections, utilize a 
similar approach, controlling release rates by increasing the surface area exposure and 
also addressing the inherent leakiness present in homogeneous systems, such as this 
study, in the absence of the tensile strain trigger.  
1.4.1 Hybrid composites with capsular/ particulate species 
In contrast to single component systems, heterogeneous composite systems 
increase drug encapsulation, slow passive drug diffusion, and allow control over bulk 
material mechanics. The capsular component (micelle, microcapsules, or nanoparticles) 
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of the device provides higher drug encapsulation and acts as an additional barrier to slow 
the diffusion of drug, especially in the absence of a tension trigger. Furthermore, the 
composite system separates the bulk mechanics from agent encapsulation, freeing the 
available choices for substrates.  
For example, Hyun et al.121 report a tension-responsive drug delivery system with 
microcapsule arrays supported on an elastomeric substrate. These isotropic buckled 
polystyrene (PS) films, processed through thermal cycling, are loaded with model drugs, 
fluorescein-isothiocyanate (FITC)-labeled dextran or rhodamine B. The final drug 
delivery device consists of sealed microcapsules, achieved by affixing the buckled PS 
film to a soft poly(dimethylsiloxane) (PDMS) substrate (Figure 6a). In agreement with 
theoretical models, increasing strain decreases the height of the microcapsules and 
increases their spacing, up to 8.5% strain, at which point the PS film fractures. Repeated 
stretching of these devices (0.1% strain/ second) to various strain magnitudes controls the 
amount of rhodamine B release. Higher strain magnitudes (7.5%) result in greater 
rhodamine B released at each event (8-12%) while lower strain magnitudes (1%) result in 
less compound released at each event (~1%) (Figure 6b). However, when FITC-dextran 
is loaded into the devices, it does not release under either static or dynamic conditions, 
which the authors attribute to its macromolecular nature: the PS membrane severely 
restricts diffusion of macromolecules, such as FITC-dextran, but allows strain-dependent 
diffusion of small molecules, such as rhodamine B. This system is, therefore, limited to 
small molecule drug delivery, and thus opportunities exist for mechanoresponsive drug 
delivery systems to deliver both small and macromolecular therapies and at higher 
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strains.  
Xiao et al.122 employ elastomeric hydrogels for the mechanoresponsive release of 
pyrene, a hydrophobic, fluorescent model drug. Block copolymer micelles (BCM) consist 
of two components: poly(n-butyl acrylate) serving as the hydrophobic portion for pyrene 
loading, and poly(acrylic acid) modified with 2-hydroxyethyl acrylate serving as the 
hydrophilic portion, which also crosslinks to the bulk polyacrylamide hydrogel by free 
radical polymerization. Stretched hydrogels transfer their macroscopic deflection to the 
BCMs through these crosslinks, causing a morphological change in the micelles that 
favors pyrene release (Figure 6c). Hydrogels stretched to 60% strain release pyrene at a 
2.5x faster rate over the first extension/relaxation interval than hydrogels stretched to 
30% strain, and release pyrene at a 5x faster rate than hydrogels incubated under static 
conditions (0% strain) (Figure 6d, top). In addition, cumulative release of pyrene over 60 
minutes (60 cycles over 5 minutes followed by 5 minutes of rest) is greatest for hydrogels 
stretched to 60% (~25% release), compared to those stretched to 30% (~15% release) and 
static samples (~10% release) (Figure 6d, bottom). Although the BCM-crosslinked 
hydrogels withstand up to 350% strain without failure, it is uncertain how these hydrogels 
perform at higher strains as the release at 60% strain is the maximum value reported.  
Di et al.123 use a similar approach, embedding alginate microparticles with drug or 
protein-loaded PLGA nanoparticles into an elastomeric base substrate (Dragon Skin 30) 
(Figure 6e). The surface area of the alginate depot increases with increasing strain, thus 
facilitating greater drug diffusion and release. Doxorubicin-formulated devices 
demonstrate strain-dependent release (100% strain releases ~3x more than 0% strain, 
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with 10 cycles with 2 seconds/ cycle) with cycle-dependent (50% strain from 0 to 10 
cycles) decrease in HeLa viability in vitro with 2D and 3D cultures. Microneedles, 
composed of hyaluronic acid crosslinked microparticles loaded with insulin, are applied 
in vivo to the skin of streptozotocin-induced diabetic mice. Blood glucose levels decrease 
over three 4-hour stretching intervals (10 cycles at 50% strain), while non-stimulated 
microneedles initially burst release (still hyperglycemic amounts) and bolus insulin 
injections reduce blood glucose levels over one 4-hour interval (Figure 6f). Releasing a 
variety of compounds upon physiological stimulation demonstrates the potential 
versatility of the system in the clinic. However, control over passive release is necessary 
to minimize resistance to chemotherapeutics or antibiotics, and to preserve the amount of 
drug or protein available for release at a later time.    
1.4.2 Layered composites 
In contrast to particulate systems, layered composite systems are another strategy 
to compartmentalize drug encapsulation and to optimize bulk mechanics for tension-
responsive delivery. Arm et al.124 describe the release of bovine albumin or trypsin 
inhibitor under cyclic tensile stress from poly(lactic-co-glycolic acid) [PLGA] thin film 
depots wrapped around poly-p-dioxanone cylindrical implants. Using cyclic three-point 
bending (0.4 Hz (30 mins/ day) for 2 weeks at 0 mm, 0.5 mm, or 1 mm deflections) as a 
model for loading in long bones, the authors demonstrate faster release rates with larger 
deflections. Albumin-loaded devices (66-68 kDa) release faster than trypsin inhibitor-
loaded devices (20 kDa), attributed to enhanced polymer degradation from larger pores 
left after the larger molecular weight albumin releases. However, this method of loading 
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provides non-uniform stresses and deformations on the implant (higher stresses on outer 
layers), and thus it is challenging to quantify and compare the necessary stress 
magnitudes for release. Other approaches for layered composites, including 
polyelectrolyte films and superhydrophobic coatings, are discussed in the following 
sections.  
1.4.2.1 Polyelectrolyte films 
The use of polyelectrolyte films, consisting of alternating layers of polyanionic 
and polycationic films, represent another strategy to control permeability by tuning the 
density of these layers.125–129 The research groups of Lavalle and Schaaf report tension-
responsive delivery systems with polyelectrolyte films that initiate drug/ protein release 
through: 1) unmasking of active entrapped enzymes; 2) enzymatic modification of 
entrapped model prodrugs; or 3) enzymatic degradation of the polymeric substrata. The 
two strata of their systems consist of a thick, low density, exponentially growing 
polyelectrolyte film (poly(L-lysine)/hyaluronic acid (PLL/HA) that sequesters drug or 
protein, and a thin, high density, linearly 
growing  (poly(diallyldimethylammonium)/poly(sodium-4-styrenesulfonate) 
(PDADMA/PSS), or poly(allylamine)/poly(styrene sulfonate) (PAH/PSS)) 
polyelectrolyte film that acts as a barrier, preventing the permeability of polyelectrolytes 
and small ions. The two strata are formed on an elastomeric PDMS substrate, capable of 
withstanding tensile strains up to 100%. 
In the first study,130 PDADMA/PSS5 layers respond to cyclic tensile strain with 
the opening of nanovalve pores. The visibility of these pores at 50% strain and 100% 
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strain led to a follow up study131 to control the activation of alkaline phosphatase (ALP) 
from PLL/HA reservoirs, capped by PDADMA/PSS6. In the absence of tension, the 
PDADMA/PSS stratum serves as an effective barrier, impeding the diffusion of ALP by 
partitioning the enzyme from the substrate, fluorescein diphosphate (FDP). Stretching the 
system past 70% critical strain (Figure 8a) thins the PDADMA/PSS layer, uncovering the 
embedded ALP, allowing dephosphorylation of FDP into fluorescein (F) in the media. 
Similarly, a subsequent study demonstrates the release and catalysis of fluorescein 
diphosphate (FDP) from PLL/HA reservoirs, capped by PDADMA/PSS10  layers 
containing adsorbed ALP (Figure 8b).132 The application of tensile strain past the critical 
threshold (40% strain) increases the permeability and diffusion of FDP due to nano-
/microscopic structural reorganization of the PDADMA/PSS barrier. The disparity in 
release from the two systems can be attributed to the difference in molecular size of the 
two compounds; ALP (enzyme) is much larger than FDP (small molecule) and thus 
requires stretching to a larger critical strain for initiate release. Consequently, adsorbed 
ALP catalyzes these freely diffusing FDP molecules into F, leading to an increase in 
fluorescence intensity based on the strain applied (up to 100%, Figure 8c). However, the 
mechanism of release differs in these latter cases unlike the PDADMA/PSS5 
polyelectrolyte layers in the first study, as there are no detectable openings in the 
PDADMA/PSS6 or PDADMA/PSS10 layers.  
While the above studies demonstrate the stretch-induced release of a model active 
enzyme and a model prodrug, their follow-up study applies the polyelectrolyte multilayer 
system to the enzymatic degradation of drug-loaded polymeric films upon application of 
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tension.133 The mechanosensitive barrier layer consists of a more solid and brittle 
material, PAH/PSS, which yields openings in the barrier with the application of tension. 
Trypsin, a protease that recognizes and acts on the C-terminus of lysine residues present 
in polypeptide chains, enzymatically degrades the PLL/HA reservoir, which is loaded 
with paclitaxel, a potent mitotic inhibitor chemotherapeutic agent. Without applied 
tension, the PAH/PSS barrier isolates the reservoir from trypsin and prevents drug 
release. However, mechanical extension to 30% strain fractures the barrier, permitting 
trypsin diffusion into the reservoir through these openings to degrade the reservoir and 
release fluorescently-labeled paclitaxel. This results in a 7-fold increase in fluorescent 
signal over 8 hours compared to non-stretched devices and devices stretched in the 
absence of trypsin, confirming the necessity of both stretch and enzymatic activity for 
drug release (Figure 8d). While the mechanism of release through these openings is 
explored, the drug release is only evaluated at one tensile strain value (30%).  
1.4.2.2 Wetting of superhydrophobic systems 
Another strategy for constructing mechanoresponsive drug delivery systems relies 
on the triggered wetting of normally non-wetting or slowly-wetting drug-loaded 
materials, and is currently used for a variety of biomedical applications.134 In this manner, 
water solubilizes the drug, causing subsequent release via diffusion into the surrounding 
aqueous environment. Mechanically-induced wetting generally employs hydrophobic or 
superhydrophobic materials with microscopic structural features that become wetted 
under stimulation.135–137 Without tension, these features render the material surface non-
wetted. Superhydrophobic surfaces, which are characterized by an advancing water 
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contact angle greater than 150° and low contact angle hysteresis,138,139 are the result of 
the synergy between a low surface energy material and its rough topology, and applying 
tension destabilizes this architecture to promote wetting at the material interface. 
In contrast to a materials approach to alter wettability through microscale features, 
the following examples use a more macroscopic approach—specifically, by introducing 
fractures within composite materials. Huang et al.140 demonstrate the ability to reversibly 
switch between superhydrophobic and superhydrophilic states with the expansion of 
various stimuli-responsive acrylamide-based hydrogels coated with silanized glass 
particles. Increases in tensile strain, pH, or temperature disrupt the superhydrophobic 
glass particle coating, revealing the underlying hydrophilic hydrogel. Although the 
authors do not demonstrate release of entrapped agents from the systems, they present 
control over dye penetration into the alginate-acrylamide hydrogel with increasing strain 
(up to 600%).  
Developing a superhydrophobic system for drug delivery, Wang and Kaplan et al. 
control drug release based on tensile strain and further integrate their system with an 
esophageal stent for ex vivo delivery.141 In the absence of tensile strain, the 
superhydrophobic coating, an electrosprayed mixture of biocompatible, biodegradable 
low surface energy polymers poly(ε-caprolactone) and poly(glycerol monostearate 
carbonate-co-caprolactone), impedes water infiltration into the hydrophilic drug core 
(composed of cellulose/polyester), in contrast to a hydrophobic coating of poly(ε-
caprolactone) (contact angle = 119°) (Figure 8e). Increasing strain (at 7% strain/s) causes 
greater stress on the superhydrophobic coating, resulting in the development of parallel 
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crack patterns (Figure 8f). The disruption of the coating facilitates the release of 
entrapped dye (Figure 8e) and chemotherapeutics at strains from 10% to 100%. The 
release of chemotherapeutics cisplatin or 7-ethyl-hydroxycamptothecin (which are 
hydrophilic and hydrophobic, respectively) result in strain-dependent dosing in vitro to 
OE33 esophageal cancer cells. Finally, expansion of esophageal stents integrated with the 
tension-responsive coatings enhances the delivery of a fluorescent dye to ex vivo bovine 
esophagus (Figure 8g). The ability to effectively load and deliver a wide range of 
compounds (both hydrophilic and hydrophobic) demonstrates the versatility of the 
system. However, the release under cyclic tension is not evaluated and leaves open the 
opportunity to design a reversible system in subsequent studies.  
1.5 Shear-responsive systems 
Shear-mediated delivery relies on reversible material deformation or 
disaggregation. Shear forces, present internally or externally (through syringe 
injections),142 can trigger release. One major area of focus for shear-responsive delivery 
is in the cardiovascular system, where narrowing of the vessels increases the local shear 
stress nearly ten-fold.143,144 Rather than relying on more conventional biochemical 
approaches based on targeting moieties (i.e., antibodies), mechanical signals physically 
target atherosclerotic plaques or clots, as discussed below.  
1.5.1 Liposome deformation 
In response to high shear environments, liposomes can release their payload due 
to lipid bilayer flexibility or when in contact with flowing fluids. Natsume and 
Yoshimoto use this principle to accelerate enzyme activity under shear flow.145 Glucose 
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oxidase (GO), encapsulated in a three-component liposome system (POPC (1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphochline), POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoglycerol), and cholesterol), exhibits minimal activity under low shear stress due 
to the partitioning of the glucose substrate from the enzyme by the liposomal membrane 
(Figure 8a). With greater laminar shear rates (up to 7.8 × 103 s-1), liposomal membrane 
permeability increases with 80% fractional conversion of glucose by GO after 180 
minutes compared to ~0% at zero shear (Figure 8b). The liposome acts as a chaperone for 
the released GO, preserving the enzymatic activity of free GO even in the presence of 
empty liposomes, compared to free GO without liposomes (decreases to 60% activity 
after 360 mins) (Figure 8c). Although the system is unique to glucose oxidase, the shear-
induced activity of the enzyme is applicable to sensors and as delivery vehicles 
responsive to shear flow.  
Holme et al. report another example of using shear to release entrapped agents 
within 1,3-diamidophospholipid-based vesicles possessing lenticular, rather than 
spherical, morphologies.146 The authors hypothesize that spherical vesicles are relatively 
robust and resistant to mechanical disruption, while the altered morphologies generated 
by the large bending moduli of modified phospholipid membranes are responsive to 
elevated shear stress due to breakage along their equators (Figure 8d). Large, unilamellar 
vesicles, composed of synthetic 1,3-dipalmitamidopropan-2-yl 2-
(trimethylammonio)ethyl phosphate lipids (Pad–PC–Pad), are prepared with entrapped 
carboxyfluorescein dye and applied to an in vitro model of atherosclerosis, simulating 
healthy (i.e., shear stress = 2 Pa) and severely constricted arteries (i.e, shear stress = 40 
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Pa). After 40 passes of Pad-PC-Pad through the constricted model, the shear-responsive 
vesicles release 70% of entrapped dye compared to only 45% dye release when passed 
through the healthy arterial model (Figure 8e). Because the authors focused their efforts 
on the design and optimization of phospholipid vesicles to achieve shear-responsive 
release, they left open the opportunity to demonstrate in vivo efficacy in a clinically-
relevant model with pharmacologically active agents. 
1.5.2 Particle aggregation and dispersion 
Microaggregates are capable of dispersing in response to shear stress, offering 
another strategy for shear-responsive delivery. Korin et al. apply their shear-responsive 
drug delivery system to an elevated shear stress model for cardiovascular disease, and 
extend their study to an in vivo murine model of myocardial infarction and pulmonary 
embolism.147 Nanoparticle microaggregates, composed of poly(lactic-co-glycolic acid) 
(50:50, 17 kDa), are stable under shear stresses commonly experienced by unobstructed 
coronary vessels (10 – 30 dyne/cm2), yet break apart upon experiencing pathologically-
relevant shear stresses (> 100 dyne/cm2) for 1 minute, increasing nanoparticle 
accumulation by nearly 6-fold (Figures 9a, 9b). In a three-dimensional PDMS 
microfluidic device that simulates a stenosis, the signal from fluorescent nanoparticles 
increases 16-fold downstream compared to particles with unobstructed flow, and 
increases 7-fold in cultured endothelial cells downstream compared to cells upstream of 
the constriction. Finally, nanoparticles formulated with the thrombolytic drug tissue 
plasminogen activator (tPA) are evaluated for thrombolytic efficacy in a mouse arterial 
thrombus model. After perfusing preformed fibrin clots, the authors restore pulmonary 
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arterial pressure ex vivo with a 100-fold lower effective dose of tPA (Figure 9c), 
demonstrating superior performance with the nanoparticle aggregates. Lastly, in an in 
vivo acute thrombus murine model (~100 clots, 150 µm), all untreated mice die within 1 
hour while 85% of treated mice survive without symptoms of respiratory distress (Figure 
9d). Marosfoi, Korin, and Gounis et al. further apply their system in vivo to a large vessel 
occlusion rabbit model.148 After complete carotid occlusion, the mice undergo a 
temporary endovascular bypass, whereby a stent is inserted and expanded at the clot site 
to temporarily restore high shear blood flow. Compared to stents alone (43% 
recanalization) and stents with free recombinant tPA (2 mg and 20 mg, 14% and 71% 
recanalization, respectively), occlusions treated with stenting and tPA microaggregates 
are all successfully recanalized.  
In contrast, Chen et al. use electrostatic forces to adsorb heparin-encapsulated 
nanoparticles onto red blood cells in order to extend drug circulation time.149 The 
nanoparticles, composed of heparin and thiolated poly-L-lysine (PLL) exhibit increased 
colloidal stability through the formation of disulfide bonds, and are electrostatically 
attracted to the negatively charged red blood cell surfaces (PLL/ heparin = 6:5 w/w, +25 
mV). Scanning electron microscope imaging reveals ~80% particle attachment under low 
shear stress (1 Pa). However, at high shear-stress (10 Pa), ~50% of the particles remain 
on the red blood cell after 24 hours, and nearly all particles detach after 48 hours, 
demonstrating shear-induced nanoparticle detachment.  
Anselmo et al. mimic another hematocyte, producing platelet-like nanoparticles to 
target vascular injuries and facilitate hemostasis.150 These particles, produced by layer-
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by-layer assemblies of poly(allylamine hydrochloride) (PAH) and bovine serum albumin 
(BSA), exhibit greater aggregation at higher shear stresses (45 mins at 5, 25, and 55 
Dynes/cm2) when surface modified with collagen-binding peptides (CBP) and von 
Willebrand Factor (vWF) binding peptides (VBP) (for wound targeting) on a collagen/ 
vWF coated glass slide, or surface modified with fibrinogen-mimetic peptide (FMP, for 
platelet binding) on glass slides with activated platelets, compared to particles lacking 
surface modifications or surface modified particles on BSA-coated glass slides. The 
authors also demonstrate greater particle aggregations after flowing the particles through 
a glass capillary. This shear strain-dependent aggregation, similar to physiological 
platelets encountering a site of vascular injury, is attributed to the interaction of FMP and 
the flexible discoid shape that concentrates particles to vessel walls. In a tail transection 
mouse model, the CBP, VBP, and FMP functionalized particles decrease bleeding time 
by ~65%. Analysis of the subsequent tail clots verify the incorporation of nanoparticle 
aggregates, as predicted in vitro, and their ability to expedite the formation of hemostatic 
plugs. 
In another approach, Mellal et al. report the dispersion of therapeutic MRI 
(magnetic resonance imaging)-guided magnetic microcarriers to deliver site-specific 
drug.151 Simulating flow through an artery, computational models demonstrate 
parameters to maximize drug loading with superparamagnetic iron oxide particle 
aggregates while maintaining the ability to navigate in arterial blood flow. Specifically, 
chain-like aggregations exhibit higher magnetic volume, to steer more efficiently, than 
spherical or ellipsoid-like aggregates. The results are experimentally verified with flow 
		
26 
through a microfluidic arterial bifurcation using 3D Maxwell-Helmholtz coils. Figure 9e 
shows the evolution of the aggregates under high shear stress (simulating 60% vessel 
occlusion) from spherical to ellipsoidal-like to chain-like structures, in accordance to 
experimental and theoretical data. With increasing shear force, the aggregation volume to 
the particle volume decreases by nearly half, disrupting the magnetic dipole-dipole 
forces. The disruption of the aggregate downstream releases drug and allows facile 
clearance of particles from the body. While the computational data supports the utility of 
aggregates, the studies do not show drug distribution after release nor does the 
experimental data demonstrate efficacious drug delivery.  
1.5.3 Supramolecular disassembly 
Self-assembled structures exhibit reversible or self-healing characteristics for 
shear-responsive delivery. Kaplan et al. report the delivery of anti-TNFα antibody upon 
the application of shear stress from a self-assembled hydrogel.152 The supramolecular 
nanofiber gel, composed of sugar, nucleoside, and fatty acid subunits, disassembles under 
increasing in shear stress (up to ~27 Pa) and reforms within 2 minutes of the removal of 
shear. The nanofiber assembly slows the diffusion of entrapped large macromolecules in 
a weight-dependent manner (e.g., 19.6 kD FITC-dextran diffuses out more than twice as 
fast as 167 kD FITC-dextran). The shear-induced disassembly of the gel expedites the 
release of anti-TNFα antibody (Figure 9f). The resulting release from 90 minutes of 10 Pa 
shear stress reduces TNFα toxicity in vitro by ~60% in L292 cells, a murine TNFα-
sensitive fibroblast cell line (Figure 9g). The delivery of anti-TNFα antibody would serve 
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as an anti-inflammatory treatment for diseases, such as rheumatoid arthritis, effectively 
neutralizing the effects of TNFα. 
1.6 Conclusions and future perspectives 
The field of mechanically-stimulated delivery is rapidly expanding with a number 
of reports demonstrating the promise of releasing pharmaceutical/ active agents in a 
controlled manner. These mechanoresponsive systems are designed to be clinically 
relevant through physiological force triggers or externally applied clinical devices. The 
dynamic nature of the human body is constantly subjected to forces; therefore 
determining triggers distinguishable from the mechanical forces routinely present in daily 
activities are key to targeting and maximizing release.  
To take advantage of compressive forces, investigators are exploring drug loaded 
porous polymer scaffolds, siloxanes, hydrogels, crosslinked micellular gels, and layer-by-
layer microparticles. Key features reported in these systems are: 1) mechanical integrity 
to withstand and respond to multiple compressions, 2) incorporation of molecular 
containers or micelles for greater loading of hydrophobic agents, and 3) dose dependent 
cyclic release. Since the first report in the late 1980s, two of nine delivery systems have 
evaluated performance in vivo: a two-component silicone implant that responds to 
compression to successfully deliver insulin, thereby reducing glucose levels in diabetic 
rats;99 and a VEGF-loaded calcium-crosslinked hydrogel that increases vascularization 
upon cyclic compression.103 
Tension-responsive systems utilize stretchable hydrogels, siloxane substrates, 
crosslinkable micelles, polyelectrolyte layer-by-layer films, and superhydrophobic 
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composites. These systems possess: 1) the mechanical strength to be subjected to high 
tensile strains, 2) capsular or layered composites to encapsulate drugs and proteins, and 
3) cycle- or strain-dependent release. Since the first report in 1997, only one delivery 
system out of nine has evaluated performance in vivo (stretched microneedles containing 
insulin microparticles prolong delivery in diabetic mice)123 and only one other delivery 
system has evaluated performance ex vivo (drug release from a superhydrophobic 
composite is triggered by the expansion of the device, integrated with an esophageal 
stent, in ex vivo bovine esophagus).141  
In contrast, shear-activated systems exhibit: 1) reversible material deformation via 
liposomes, 2) disaggregation of microparticles or nanofibers to release their payload, or 
3) accumulation of aggregates at the target site. Well-characterized increases in 
physiological forces, such as the increase in shear stress noted at strictures in the 
cardiovascular system,143,144 act as both viable mechanical triggers and drug targets. At 
the time of this publication, there are three reports of in vivo assessment: the delivery of 
tissue plasminogen activator that dissolves clots in both an acute thrombus murine model 
and a large vessel occlusion rabbit model,147,148 and the aggregation of platelet mimics 
that decrease in bleeding time in a tail transection mouse model.150 
Overall, in comparison to other stimuli-responsive systems, there are only a 
handful of reports on the mechanoresponsive delivery of active therapeutics. The ease of 
characterization with model dyes or compounds demonstrates proof-of-concept, but to 
translate mechanoresponsive systems to the clinic, the delivery of therapeutic agents in 
vivo will need to be further developed. Currently, there are no mechanically-activated 
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drug delivery devices approved for use in patients, although numerous opportunities exist 
for new designs of drug-device combinations to enhance treatment of cardiovascular, 
musculoskeletal, and pulmonary diseases. For example, the increase in stress within 
vessels containing atherosclerotic plaques and arterial embolisms allow physical rather 
than biochemical targeting to stenotic sites for drug release. Liposomes and 
microaggregates deform and disaggregate, respectively, under a higher shear 
environment to release their payloads. Treatment can also be enhanced by integrating 
mechanoresponsive drug or protein delivery systems with existing mechanical medical 
devices, such as stents and catheters. The radial expansion of esophageal stents, which 
treat esophageal cancer, acts as a trigger to control delivery of chemotherapeutics.141 
Other systems offer new mechanical approaches to treatment; user-controlled delivery of 
drugs and proteins are reported for pain management, neoangiogenesis, and diabetes.  
While we report these promising mechanoresponsive examples, many 
opportunities and challenges exist for the future of these systems. Current compressive 
systems, composed of elastomeric substrates and hydrogels, successfully withstand 
repeated compressions and will need to be continually developed to maximize agent 
encapsulation and minimize release in the absence of compression. The ease of externally 
applying these compressive forces on implanted systems has resulted in increased interest 
in these systems, but improved characterization and precise application of these forces 
are needed to reduce the variability in dosing.  
Similarly, well-characterized tensile forces should be used as triggers. The robust 
characterization and increasing deployment of mechanical medical devices, such as 
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balloon catheters and stents, has led to their use as viable triggers to further enhance 
current medical care. Towards these applications, tension-responsive systems should 
tolerate higher strains (>30%), and this has been demonstrated in many of the current 
systems using hydrogels, siloxanes, and polyester meshes. The problems encountered 
with first generation systems, such as limited loading of agents and diffusive release in 
the absence of tensile triggers, are being resolved through capsular and layered 
composites.  
In contrast, shear-responsive systems rely on the reversible deformation of lipids 
in liposomes, or the dispersion of microparticle or nanofiber aggregates to release the 
loaded therapeutics. The majority of reports on shear-responsive delivery focus on 
cardiovascular indications (i.e., atherosclerosis) as the increase in shear stress, due to 
narrowing of blood vessels, provides a pathophysiological trigger for site-specific 
delivery.  
The diversity of active therapeutic agents, as opposed to model dyes and 
compounds, investigated in shear, tension, and compression activated system is minimal 
in the compositional and structural space. For example, there are no examples of nucleic 
acids being delivered by such systems, and delivery of only one type of growth factor 
(VEGF),103 one type of antibody (anti-TNFα)152 three proteins/ enzymes (insulin,99,123 
glucose oxidase,145 tissue plasminogen activator147,148), one polysaccharide (heparin),149 
and seven small molecules (ondansetron,106 hydrocortisone,107 dexamethasone,108 
doxorubicin,123 paclitaxel,133 cisplatin,141 and camptothecin141) has been described. 
Delivery is further complicated by the necessity to preserve the activity of small 
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molecules and proteins within the mechanoresponsive systems. Lastly, in all these cases 
long-term assessments of implant materials and the development of biodegradable 
substrates are needed before clinical translation becomes feasible.  
The various systems described utilize a number of different delivery strategies, 
from inducing flux through increased pressure (hydrogels, elastomers under compression) 
to increasing the available surface area or porosity to expedite diffusion (liposomes, 
hydrogels, elastomers under shear/ tension). Many of the release compounds are not 
chemically conjugated to the matrix; instead they are physically incorporated and thus 
rely on a diffusive gradient increase to exudate compounds. One exception to this case is 
the mechanochemical activation of oxanorbornadiene bonds, where the application of 
physical force breaks chemical bonds to release, albeit also limits release to, a furan-
derivative.102 However, the reliance on diffusion for many of these systems has led to 
strategies to prolong drug release. Inclusion complexes,106,107 micelles,108,153 and 
particles100,123,147,149 increase loading of hydrophobic compounds while also allowing 
retention for a longer time period in the absence of mechanical stimuli. Furthermore, as 
additional drug carrier systems, they act as an additional rate-limiting step to compound 
release. In contrast, other studies have sought to expedite release. In one example, 
stretching exposes the drug reservoir to enzymatic degradation of the matrix, resulting in 
release. Nevertheless, much of the release kinetics also depends on the physical 
properties of the drug and their dissolution into release media. Of the 26 studies, only 
three have reported using compounds of varying hydrophobicities, charge, or molecular 
weight.109,121,141 In general, there is higher loading and release of small neutral molecules, 
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compared to charged or higher molecular weight compounds. Studying various release 
compounds is especially critical for systems that utilize mechanical targets (i.e., 
increasing shear at vessel strictures) to determine the optimal drug with the proper 
dosing.  
The examples highlighted in this chapter demonstrate both the capabilities and 
limitations of mechanically-activated systems. Challenges for many of the 
mechanoresponsive delivery systems reported thus far are a) response over a limited 
range and b) struggling to prevent release (i.e., burst release or leaky release) in the 
absence of stimuli. Additionally, many of these systems utilize large forces to trigger 
drug release and thus materials that can respond to smaller cellular forces represent an 
unexplored and critical area of research. Harnessing mechanical forces, either internal or 
external, to control the release of active agents in vivo is a viable strategy for drug 
delivery with significant clinical promise in the near future. 
The motivation for writing this chapter is to recognize the research achievements 
to date, to stimulate discovery of new mechanoresponsive delivery designs and device 
compositions, and to encourage all to work in this exciting area of drug delivery.  
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Figure 1. Physiological and external forces and their relative magnitudes present in the 
body. 
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Figure 2. Schematic representation of compressive, tensile, and shear forces. 
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Figure 3. Compressive elastomeric systems. (a) Reduction of blood glucose in rats with 
the release of insulin from silicone implants upon stimulation every 2 days. (b) Schematic 
representation of release when compression of the device reaches the critical strain (εc). 
Release profile of rhodamine B with three bending events with bending radius of (c) 45 
mm, and (d) 19 mm. (e) Modulation of release with channel volume. Figures are 
reprinted from Refs. [99] and [101].  
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Figure 4. Compressive alginate systems.  (a) Release of VEGF in vitro from alginate 
hydrogels upon mechanical compression. (b) Increase in blood vessel density with loaded 
and mechanically stimulated hydrogels (+/+), compared to unloaded hydrogels with no 
mechanical stimulation (-/-), unloaed hydrogels with mechanical stimulation (-/+), and 
loaded hydrogels with no mechanical stimulation (+/-). (c) Photomicrographs of tissue 
sections with blood vessels (arrows) in loaded hydrogels without mechanical stimulation 
(+/-, top) and loaded hydrogels with mechanical stimulation (+/+, bottom). (d) Schematic 
representation of β-cyclodextrin conjugated alginate system with multiple crosslinks 
(left) and single link (right). (e) Release profile from crosslinked β-cyclodextrin alginate 
gels, modulating release based on strain (50%, 30%, 0%). Solid purple arrows represent 
one-time compressions, red empty arrows represent five-cycle compressions. Figures are 
reprinted from Refs. [103] and [106]. 
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Figure 5. Compressive hydrogel systems.  (a) Schematic representation of 
dexamethasone-encapsulated micelles (xBCM(DEX)) crosslinked to hyaluronic acid-
based matrix (HAGMA). (b) Mechanical stimulation (top) and resulting release profile 
(bottom) from xBCM(DEX) crosslinked to HAGMA. (c) Mechanical stimulation (top) 
and corresponding release (middle) and cumulative release (bottom) of FITC 
encapsulated in chitosan-alginate layers with silica nanoparticles (1L-HHC) compared to 
chitosan-alginate layers (control). Release is modulated by force applied (d) and addition 
of more layers (e). Figures are reprinted from Refs. [108] and [109].  
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Figure 6. Tensile capsular/ particulate composite systems.  (a) Buckled polystyrene films 
with entrapped rhodamine. (b) Release of rhodamine with increasing tensile strain. (c) 
Increasing strain deforms pyrene-loaded micelles crosslinked to polyacrylamide matrix to 
facilitate release. (d) Release rate (top) and cumulative release (bottom) of pyrene with 
various strains (0%, 30%, 60%). (e) Schematic representation of drug-loaded 
nanoparticles encapsulated in alginate microgel depots, further embedded into an 
elastomeric film. (f) Decrease in blood glucose levels with the mechanical stimulation of 
insulin-loaded microneedles in vivo. Figures are reprinted from Refs. [121], [122], and 
[123]. 
  
		
39 
 
 
Figure 7. Layered tensile-responsive systems. (a) Increase in enzyme activity results in 
increased fluorescence past the critical strain (70%). (b) Schematic representation of FDP 
release from PLL/HA polyelectrolyte layers and subsequent catalysis by enzyme ALP 
into fluorescein by stretching. (c) Increase in fluorescence as an indicator of enzymatic 
activity with increasing tensile strain. (d) Increase in fluorescent intensity with paclitaxel-
oregon green release under mechanical stimulation. (e) Modulation of release of dye 
based on strain from superhydrophobic and hydrophobic composites (PCL). (f) Crack 
patterns in the superhydrophobic coating with increasing strain facilitate release. (g) 
System integrated with esophageal stent delivers dye to ex vivo esophageal tissue (under 
UV light, left) and corresponding cross-section (right, T = tissue, L = lumen). Figures are 
reprinted from Refs. [131], [132], [133], [141].  
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Figure 8. Liposomal shear responsive systems.  (a) Schematic representation of liposomal 
chaperone that increases glucose oxidase activity with increasing shear stress. (b) 
Corresponding conversion of glucose oxidase with shear. (c) Glucose oxidase activity 
with encapsulated enzyme, free enzyme, and in the absence of liposomes. (d) Schematic 
representation of delivery to plaque upon increase in shear stress. (e) Release of dye with 
untreated vesicles, model healthy arteries, and model constricted arteries. Figures are 
reprinted from Refs. [145] and [146]. 
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Figure 9. Shear-responsive aggregate systems.  (a) Nanoparticle aggregates disperse with 
increase in shear stress. (b) Increase in nanoparticle accumulation under pathological 
shear stress compared to normal shear stress. (c) Pressure recovery with 1/100 less dose 
in nanoparticle aggregates, compared to bolus injection. (d) Survival of mice after 
treatment in acute thrombus model. (e) Theoretical and experimental dispersion of 
magnetic iron oxide particles in model artery. (f) Schematic representation of anti-TNFα 
delivery upon application of shear. (g) Delivery of anti-TNFα and neutralization of TNFα 
in vitro with increasing shear. Figures are reprinted from Refs. [147], [151], and [152]. 
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CHAPTER 2: Stretch-induced drug delivery from superhydrophobic polymer 
composites 
Adapted from: Stretch-induced drug delivery from superhydrophobic polymer 
composites: use of crack propagation failure modes for controlling release rates, 
Angewandte Chemie International Edition. 2016; 128(8):2846-2850. 
2.1 Abstract 
The concept of using crack propagation in polymeric materials to control drug 
release and its first demonstration are reported. The composite drug delivery system 
consists of highly-textured superhydrophobic electrosprayed microparticle coatings, 
composed of biodegradable and biocompatible polymers poly(caprolactone) and 
poly(glycerol monostearate carbonate-co-caprolactone), and a cellulose/polyester core. 
The release of entrapped agents is controlled by the magnitude of applied strain, resulting 
in a graded response from water infiltration through the propagating patterned cracks in 
the coating. Strain-dependent delivery of the anticancer agents cisplatin and 7-ethyl-10-
hydroxycamptothecin to esophageal cancer cells (OE33) in vitro is observed. Finally the 
device is integrated with an esophageal stent to demonstrate delivery of fluorescein 
diacetate, using applied tension, to an ex vivo esophagus. 
2.2 Introduction 
Mechanoresponsive polymeric materials are of significant interest as key 
functional elements in self-healing assemblies,154–161 sensors and electronics,110,162–165 and 
biology/medicine.166–170 Consequently, mechanoresponsive materials are actively being 
developed that respond to mechanical stimuli such as compression,100,103,106,108 
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tension,119,132,133 shear,146,147,171 or ultrasound.172–174 Implanted medical devices also 
experience many of these forces, and even exert their own mechanical forces during use 
(e.g., stents).175,176  Our approach to designing functional mechanoresponsive materials 
for drug delivery uses crack propagation failure modes of composite materials to control 
drug release. We hypothesized that crack formation could be initiated and propagated 
through superhydrophobic coatings on a multilayered drug delivery system by applying 
tension, with consequent device wetting and drug release. Given our interests in triggered 
drug release from polymeric7,8 and superhydrophobic177,178 materials, we realized an 
opportunity to design and evaluate such a new drug delivery system for an esophageal 
stent. Herein, we report: (1) the fabrication of a multilayered electrosprayed polymeric 
device; (2) the entrapment and subsequent controlled release of both hydrophilic and 
lipophilic agents under various applied strains; (3) analysis of the crack propagation 
mechanism with determination of the fracture toughness and critical strain energy release 
rate; (4) the demonstration of in vitro tension-mediated delivery of cisplatin and 7-ethyl-
10-hydroxycamptothecin (SN-38) to cancer cells; and (5) the integration of the device 
with an esophageal stent to demonstrate fluorescein diacetate delivery, using applied 
tension, to an ex vivo esophagus.  
2.3 Materials and methods 
By design, the device consists of a hydrophilic mesh core (containing release 
agent) encased by two superhydrophobic coatings that resist overall wetting. The 
mismatch in mechanical properties, resulting from a strong core and weaker coating, 
ensures mechanical failure of the coatings in the presence of applied tension, with crack 
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propagation leading to water infiltration and release of the agent. Specifically, the 
absorbent cellulose/polyester core is rendered water-impermeable by electrospraying its 
entire surface with a low surface energy polymer blend. We selected electrospraying 
(Figure 10a) to produce superhydrophobic coatings, as opposed to other processing 
techniques,179–184 due to its ability to generate coatings of interconnected, hydrophobic 
micro- and nanoparticles on otherwise hydrophilic bulk materials, and because it is an 
industrial scalable technique.185 The combination of low surface energy from the blend of 
two biodegradable, biocompatible polymers (polycaprolactone (PCL, Mw = 45 kg·mol-1) 
and poly(glycerol monostearate carbonate-co-caprolactone) (PGC-C18, Mw = 30 
kg·mol-1),186 (Figure 10a)), and high surface roughness from electrospraying, are 
requisites for eliciting superhydrophobicity (advancing water contact angles > 
150°).139,187 Hydrophilic meshes (250 µm thickness) homogenously loaded with dye or 
anticancer agents are electrosprayed with a 100 µm-thick coating (Figure 10b). Cross-
sectional SEM image (Figure 10c) shows the three layers of the device, with coatings 
composed of interconnected particles of 2-7 µm diameter (Figure 11a); these 
superhydrophobic surfaces exhibit advancing water contact angles approaching 170° as 
opposed to hydrophobic PCL electrosprayed surfaces with advancing contact angle of 
119° (Figure 10d). Without these superhydrophobic coatings, the hydrophilic core rapidly 
absorbs water and organic solvents. This indiscriminate absorbency also permits a variety 
of molecular agents to be loaded and studied. 
Polymer Synthesis. Poly(glycerol carbonate-co-ε-caprolactone) (PGC),  the precursor 
polymer, was prepared as previously described and characterized.188 The final copolymer, 
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poly(glycerol monostearate carbonate-co-ε-caprolactone (PGC-C18) (1:4 comonomer 
ratio, Mw = 30 kg·mol-1, PDI = 1.4), was purified by repeated precipitations in cold 
methanol.  
Device Fabrication: Solutions of dye, cisplatin, SN-38, or fluorescein diacetate were 
adsorbed onto cellulose/polyester meshes and electrosprayed with a solution of 1:1 PGC-
C18 (Mw = 30 kg·mol-1, PDI = 1.4) and PCL (Mw = 45 kg·mol-1) (flow rate = 5 mL hr−1, 
voltage = 20 kV, tip-to-collector distance = 10 cm). Each mesh was loaded with 50 µL of 
stock drug solution (25 mg/mL cisplatin, 1 mg/mL SN-38), resulting in 1.25 mg of 
cisplatin per mesh or 0.05 mg of SN-38 per mesh. This corresponds to 2.4 wt% cisplatin 
drug loading and 0.1 wt% SN-38 drug loading, and encapsulation efficiencies of 97.8 +/- 
8.8% and 97.1 +/- 4.8%, respectively. 
Tension-Mediated Release Studies: Devices were stretched at 7% strain·s-1 in a bath PBS 
or RPMI, with 10% v/v FBS, and aliquots (2 mL) were withdrawn from the bath at 
predetermined timepoints. Dye concentrations in release media (PBS with 10% FBS) 
were measured using a HP 8453 UV-Visible spectrophotometer at 630 nm and compared 
to a standard curve. The concentration of cisplatin in release media (RPMI with 10% 
FBS) at each time point was measured using a Varian AA240Z atomic absorption 
spectrophotometer (265.5 nm) with pyrolitic carbon-coated graphite tubes and Zeeman 
background correction.189 SN-38 aliquots were mixed 1:3 with 20 mM borate buffer (pH 
9), to convert all of the SN-38 to its carboxylate form, and their concentrations 
determined using a PTI QuantaMasterTM 300 fluorimeter (λex = 380 nm, λem = 550 nm) 
and compared to a standard curve.  
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Characterization & Instrumentation. Contact angle measurements (apparent, advancing, 
and receding) were conducted with deionized water on a Kruss DSA100 goniometer. 
Samples for scanning electron microscopy (SEM) were mounted on aluminum sample 
stubs with double-sided copper tape and sputtercoated with 5 nm of gold-palladium alloy 
to reduce charging. Samples were imaged with Zeiss SUPRA 40VP field emission SEM 
with an acceleration voltage of 2 kV, and particle size was analyzed with ImageJ 
(National Institutes of Health). The integrity and coverage of coatings was confirmed 
(Figure 11), contact angles goniometry, and probing the entire surface with a hanging 
droplet of deionized water. Mechanical (tensile) measurements were obtained using an 
Instron 5848 Microtester with a 100N load cell. Microcomputed tomography studies were 
performed by submerging devices in a solution (80 mgI/mL) of iodixanol (GE 
Healthcare) for 5 minutes. While submerged, devices were elongated to a strain 
magnitude of 1.0. Water infiltration (i.e., contrast agent solution) was measured using a 
Scanco Medical µCT40 imaging system as previously described,190 using an isotropic 
voxel resolution of 36 µm3, 70 kVP tube voltage, 114 µA current, and 300 ms integration 
time. Image slices were converted into the standard image format (DICOM) using 
proprietary software from Scanco Medical. Data were reconstructed and analyzed using a 
commercial image processing software (AnalyzeTM, Mayo Clinic). 
Cellulose-Polyester Mesh Porosity. SEM images (Figure 11b and 11c) were segmented 
by ImageJ such that the fibers in the focal plane were visible. From the segmented 
images, porosity was calculated by dividing the black space by the total area, resulting in 
75.1 +/- 2.9% mesh porosity.  
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Fracture & Mechanical Analysis. Crack propagation patterns were recorded on high 
definition video during elongation/tensile tests. PDMS samples were prepared by mixing 
(10:1) elastomer base with curing agent, and allowed to cure for 48 hours at room 
temperature. Both sides of the compact tension specimen were sputtercoated with gold to 
enhance conductivity for electrospraying. Control samples were fabricated with identical 
geometry and sputtercoating, but were not subsequently electrosprayed. Compact tension 
specimens were elongated at 7% strain/s, in accordance with ASTM Standard D 5049-99 
(Figure 12b). KIc and GIc were calculated as described in text for samples with and 
without electrosprayed coatings (n = 3) from force-displacement curves (Figure 12a). 
Briefly, the parameters were calculated as: 					𝐺#$ = 	 𝑃	𝑑𝑢)*+ ,              (Equation 1) 
and PQ represents the intersection of the force-displacement curve at a 5% offset from the 
linear regime, and  𝐾#$ = ( )*.∗012)( 456 +.8895:.9:6;<=.=4625<:.>46?;@.96A<;6 ?2 ),     (Equation 2) 
where  		𝑥 = C0 = $DC$E	FGHIJKLMG$NOGH	PNQJK . 
Additionally, the modulus was calculated by normalizing for volume fraction of the 
electrosprayed coating in relation to the PDMS substrate (0.85 PDMS:0.15 
electrosprayed coating). 
Cell Culture Assays. OE33 cells were maintained in RPMI + 10% FBS in a humidified 
incubator with 5% CO2.  Cells were seeded in 12-well plates at a density of 2 × 104 
cells/well and allowed to adhere for 24 hours. Aliquots of release media (1 mL) following 
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application of different strain magnitudes were sterile-filtered through 0.22-µm 
membranes and pre-incubated at 37 °C and 5% CO2 for 30 minutes to equilibrate pH. 
Medium in cell-containing wells was then aspirated and replaced with pre-incubated 
aliquots of control or release media. The cells were further incubated for 96 or 72 hours 
(SN-38 and cisplatin, respectively). Cell viability was measured using the tetrazolium-
based colorimetric MTS assay (absorbance read at 492 nm). 
Ex Vivo Delivery via Esophageal Stent. Mechanoresponsive devices were fabricated with 
fluorescein diacetate as release agent. The devices were sutured together and onto self-
expanding metal esophageal stents (Changzhou Health Microport Medical Device Co., 
Ltd, 22 mm diameter, 140 mm length, silicon coating, Ni-Ti alloy). The stent system was 
inserted into bovine esophagi (Research 87) and expanded. After 8 hours under humid 
conditions, the esophagi were opened longitudinally to expose the inner mucosal layer. 
Photographs were taken with and without UV light. Esophagus cross-sections were 
subsequently submerged in Tissue-Tek OCT and frozen to prepare 100 µm slices for 
imaging on an inverted fluorescence microscope (Olympus IX 81; λex = 490 nm, λex = 
525 nm). ImageJ software was used to quantify gray value intensity from fluorescent 
microscopy images. The fluorescence intensity of the unexpanded control (ε = 0) was 
subtracted from the fluorescence of the expanded system (ε = 1.0) with intensity greatest 
at the mucosal-device boundary. 
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2.4 Results and discussion 
2.4.1 Tensile-strain modulated dye release from superhydrophobic composites 
The tension-mediated release of agents from these multilayered devices is readily 
visualized using a hydrophilic green dye and quantified by UV-Visible 
spectrophotometry. These devices do not wet when submerged in simulated biological 
fluid (PBS with 10% FBS) for prolonged durations (> 24 hours). When subjected to 
tension, however, disruption of this otherwise superhydrophobic barrier occurs via 
coating fracture and causes subsequent dye efflux. Importantly, dye release rates are 
controlled by the magnitude of applied strain input (Figure 13a). All release aliquot 
concentrations after application of strain are significantly higher than those measured in 
the absence of strain (ε = 0), and aliquot concentrations of dye for ε = 0.1 and ε = 0.3 are 
significantly different from ε = 1.0 after 5 minutes and 10 minutes, respectively (ANOVA 
one-way, p < 0.05). Electrosprayed coatings that are merely hydrophobic (PCL, θadv = 
119°, Figure 10d) rapidly wet even in the absence of tension, confirming the necessity of 
superhydrophobic coatings to prevent release.  
2.4.2 µCT analysis of water infiltration 
Water infiltration upon coating fracture is observed also using contrast-enhanced 
microcomputed tomography (µCT) by subjecting the superhydrophobic devices to 
tension (ε = 1.0) while submerged in a solution of PBS with 10% FBS and iodixanol. As 
shown in Figure 13b, µCT attenuation between un-stretched (left) and stretched (right) 
devices noticeably differ due to the compromised superhydrophobic coating and 
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consequent core hydration after applying tension. Because bulk wetting of the coating 
does not occur, as visualized by the minimal attenuation at the outer layers of the device, 
the mechanism of release is attributed to core hydration by water infiltrating through the 
fractured superhydrophobic coatings.  
2.4.3 Crack analysis under tensile strain 
Next, we investigated the mechanism of release using fracture image analysis and 
tensile testing. The image sequence in Figure 13c shows the effect of increasing tensile 
strain (ε = 0 to 1.0) to initiate release. Mode I macroscopic crack initiation occurs at 
strain magnitudes of ~0.3, followed by propagation and additional crack formation as 
strain increases. As shown in Figure 13d and 13e, the number of cracks increases at first 
and then begins to decrease as the cracks merge with one another, resulting in greater 
mean crack area with increasing strain. As a result, more of the core surface area is 
exposed, leading to faster release rates. These fracture patterns are reminiscent of those 
found in thin films adhered to rigid, deformable substrates,191 which consist of periodic 
parallel cracks formed perpendicular to the direction of applied strain. Mechanical 
analysis in accordance with ASTM Standard D 5049-99, using a polydimethylsiloxane 
(PDMS) substrate analog of our cellulose/polyester mesh system (see Supporting 
Information), estimates plane-strain fracture toughness (KIc) and critical strain energy 
release rate (GIc) at 0.0103 ± 0.00165 MPa·m1/2 and 1.253 ± 0.595 N·mm-1, respectively. 
These KIc and GIc values represent a lower limit of fracture resistance in terms of applied 
stress and strain of the coating, respectively. Using the KIc and GIc values, and accounting 
for the volume fraction of the two materials, the Young’s modulus (E) of the coating is 
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estimated through the relation 𝐸 = STU2 (<;	V2)WTU ,     (Equation 3) 
resulting in a value of 0.0303 ± 0.014 MPa—two orders of magnitude lower than the core 
substrate (3.2 MPa). Together with KIc and GIc, E of the coating and substrate describe 
the favorable conditions for forming cracks and their subsequent morphology,192,193 and 
will aid in the design considerations for future tension responsive systems.  
2.4.4 Mechanoresponsive drug delivery for the treatment of esophageal cancer 
Mechanoresponsive drug delivery systems can be integrated with and controlled 
by current medical devices. Specifically, radially expanded esophageal stents are used for 
the palliative treatment of esophageal cancer. Esophageal cancer is the sixth deadliest 
cancer worldwide with a 5-year survival rate of 17.5%.194,195 Patients typically have 
difficulty swallowing solid and liquid food due to tumor ingrowth. In order to mitigate 
symptoms, esophageal stents are often used to keep the esophagus open to improve intake 
of nutrients, increasing patient comfort, and quality of life. Our composite system can be 
an outer polymeric sheath that is stretched with stent expansion, enabling mechano-
triggered control over drug delivery while minimizing side effects, eliminating drug loss 
during stent deployment, enabling increased drug dose, and providing easier patient 
nutrient intake. As the first steps towards this demonstration, we studied the release of 
two chemotherapeutic agents (cisplatin or SN-38) from the device, and integrated the 
device with an esophageal stent to deliver localized fluorescein diacetate ex vivo using 
applied tension.  
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2.4.5 In vitro dosing of cisplatin and SN-38 to esophageal cancer cells 
In vitro efficacy of cisplatin or SN-38 delivery (2.4 wt% and 0.1 wt% loading 
capacity, 97.8+/-8.8% and 97.1+/-4.8% encapsulation efficiency, respectively) from the 
multilayer tension responsive device is evaluated against the OE33 human esophageal 
cancer cell line. As shown in Figure 14a, the release profile for cisplatin is similar to the 
hydrophilic dye. Statistically significant differences in release from the control (ε = 0) are 
achieved starting at 2 minutes at ε = 1.0 and after 40 minutes for both ε = 0.1 and 0.3. 
Likewise, strain-dependent release rates are observed with SN-38-loaded devices, but 
over a longer duration because SN-38 is lipophilic (Figure 14b). Statistically significant 
increases of SN-38 release occur after 0.5 hour and 2.5 hours between the control and ε = 
1.0 or ε = 0.5, respectively. Release aliquots from drug-loaded devices elicit efficacy 
(cytotoxicity) against OE33 cells only after applying strain (Figure 14c and 14d). In vitro 
dose response is reflected in the significantly different cell viabilities achieved by varying 
the applied strain magnitude of cisplatin-loaded devices from 0 (control), 0.3, and 1.0 
after 30 minutes. Similar strain-dependent dose-response behavior is observed using SN-
38-loaded devices subjected to strain magnitudes of 0, 0.5, and 1.0 after 15 minutes. All 
tests were conducted with ANOVA one-way (p < 0.05). The difference in release kinetics 
of these two chemotherapeutic agents are attributed to inherent differences in aqueous 
solubilities, as cisplatin is hydrophilic and SN-38 is lipophilic.  
2.4.6 Stent integration and delivery to ex vivo tissue 
Localized ex vivo delivery is accomplished by integrating the tension-responsive 
device with a metal esophageal stent. Fluorescein diacetate was chosen as the release 
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agent due to its strong fluorescent signal after hydrolysis into fluorescein (λex = 490 nm, 
λem = 525 nm) to enable visualization of dye delivery. The fluorescein diacetate loaded 
devices were sutured around a self-expanding Ni-Ti alloy esophageal stent to form an 
enveloping sheath, capable of undergoing radial expansion with the stent. Next, the stent 
was inserted into excised bovine esophagi, and expanded to ε = 1.0. Current esophageal 
stents on the market can be expanded to a broad range of strains, from ε = 0.14 to 2.83, 
via selection based on various diameters of stents and introducers.196 After 8 hours, the 
esophagi were dissected longitudinally to reveal a fluorescent band corresponding to the 
tension-responsive device under UV light (Figure 15a and 15b). The fluorescence from 
the expanded systems (ε = 1.0) is greater than the unexpanded controls (ε = 0) in 
subsequent esophageal cross-sections (100 µm thickness) with better lumenal localization 
to the esophageal epithelial mucosa layer (Figure 15c and 15d).  
2.5 Conclusion 
While selective wetting of superhydrophobic materials and stimuli-responsive 
drug delivery are active areas of functional materials research,172,197–199 the tension-
induced wetting of a superhydrophobic material via crack propagation departs from 
previously reported approaches. For example Zhang et al.137 used a triangular polyamide 
mesh to reversibly transition from superhydrophobic to superhydrophilic (i.e., wetting) 
states using equibiaxial strains greater than 120%. This wetting transition was due to an 
increase in the average side length of the triangular net-like pores, which reduced surface 
roughness, thus overcoming the droplet surface tension and causing its collapse. 
Recently, Huang et al.140 demonstrated the ability to reversibly switch between 
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superhydrophobic to superhydrophilic states and achieved wetting triggered by increases 
in strain, pH, or temperature due to expansion of various hydrogels coated with silanized 
glass particles. Specifically, the amount of strain applied could control hydrophilic dye 
penetration into the alginate-acrylamide hydrogel. Choi and coworkers135 demonstrated a 
similar approach using absorbent fabrics that were rendered omniphobic by dip-coating 
in a solution of fluorodecyl polyhedral oligomeric silsesquioxanes. Wetting of these 
omniphobic surfaces by a variety of polar and non-polar solvents was achieved using 
equibiaxial strains greater than ~20%, depending on droplet surface tension. 
Alternatively, Di et al.123 reported a mechanism for controlling release by increasing the 
available surface area for drug diffusion. The multicomponent system consists of drug-
loaded poly(lactic-co-glycolic acid) nanoparticles incorporated in alginate microdepots, 
which are elongated as the underlying elastomeric substrate is stretched, to demonstrate 
cycle-dependent release. While these approaches provide a basis of controlling release 
through changes in microscale surface features to alter wettability or diffusivity, our 
study employs a more macroscopic approach—specifically, by introducing fractures 
within composite materials. 
We describe the fabrication, characterization, and evaluation of a tension-
responsive drug delivery system. The superhydrophobic microparticle coatings are 
applied to core substrates using a facile and scalable electrospraying process, which 
provides flexibility in substrate choice and the potential to incorporate these 
mechanoresponsive systems onto existing medical devices to enhance their current 
functionality. The key design feature responsible for the tension-triggered release of 
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entrapped agents is facilitating crack initiation and propagation within these coatings due 
to their mismatch in mechanical properties with the core material. The device is amenable 
to delivery of both lipophilic and hydrophilic agents, suggesting widespread utility for a 
number of drug delivery applications where mechanical force, such as tensile strain or 
device expansion, are experienced. 
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Figure 10. Fabrication schematic and concept of tension-responsive system. (a) The 
PGC-C18 and PCL electrosprayed barrier coating (yellow) prevents release from the 
drug-loaded core (green). (b) Photographs of the native mesh with no dye, after dye-
loading, and after subsequent coating. Tension is applied to the spray-coated system 
(bottom) longitudinally. (c) SEM image of device cross-section shows consistent 
morphology of microparticle coatings surrounding mesh core. (d) Advancing water 
contact angles for electrosprayed hydrophobic (top, PCL) and superhydrophobic (bottom, 
PCL:PGC-C18 1:1) coatings. 
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Figure 11. SEM images of composite morphology including (a) electrosprayed 
superhydrophobic coating (scale bar = 10 µm). SEM image of (b) core cellulose/polyester 
mesh and (c) corresponding segmented image. 
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Figure 12. Mechanical analysis of PDMS-coating specimens. (a) Force-displacement 
trace of electrosprayed sputtercoated PDMS under tension at 2 mm/s. (b) Photographs of 
electrosprayed sputtercoated “compact tension” specimens testing in accordance with 
ASTM Standard D 5049-99 under no tension (top) and tension.   
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Figure 13. Strain-dependent release of model hydrophilic dye from a tension-responsive, 
superhydrophobic drug delivery system via crack propagation.  (a) Cumulative dye 
release with electrosprayed coating of PCL:PGC-C18 1:1, or PCL (control, orange 
hexagon) as a function of tensile strain. Error bars denote + SD, n = 3 for each time point. 
(b) Contrast-enhanced microcomputed tomography (µCT) images before and after 
applied tensile strain (left and right, respectively), indicating water absorption (blue) after 
coating fracture. Arrowheads define the boundary of the device. (c) Image sequences 
from video as device is stretched along the x-axis showing crack development in the 
superhydrophobic barrier coating. (d) Coating fracture analysis in terms of number of 
cracks and total crack area as a function of increasing strain, n = 1. (e) Average crack 
area as a function of increasing strain, n = 1. 
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Figure 14. Tension-responsive release of chemotherapeutic agents from the 
superhydrophobic multilayered device. Cumulative release of (a) cisplatin, and (b) SN-
38. Corresponding strain-dependent dose response of in vitro (c) cisplatin and (d) SN-38 
delivery to esophageal cancer cells (OE33) after 30 minutes and 15 minutes, respectively. 
Error bars denote + SD with * = p < 0.05, n = 3 for each time point. 
  
		
61 
 
Figure 15. Ex vivo delivery of fluorescein diacetate from superhydrophobic 
devices.Photographs of tension-responsive device integrated with esophageal stent (ε = 
1.0) and fluorescein diacetate delivery (yellow, green) to bovine esophagus under (a) 
white and (b) UV light. Scale bar (white) = 20 mm. (c) Representative bright field (left) 
and fluorescent (right) microscopy images of esophagus cross-section after delivery. T 
denotes esophageal tissue and L denotes lumen space. Scale bar (red) = 2.5 mm; yellow 
arrow represents analysis profile. (d) Fluorescence intensity profile across esophagus 
cross-section. Blue dotted line represents mucosal-device boundary; error bars denote ± 
SD for n = 4. 
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CHAPTER 3: Tension-activated delivery of small molecule and protein from 
superhydrophobic composites 
Adapted from: Tension-activated delivery of small molecules and proteins from 
superhydrophobic composites, Advanced Healthcare Materials. 2017, In Press. 
3.1 Abstract 
We report the fabrication and performance of mechanically-responsive multilayer 
superhydrophobic composites. The application of tensile strain triggers the release of 
small molecules and proteins from these composites, with different tensile strain 
magnitudes and coating thickness influencing agent release. These mechanoresponsive 
composites consist of an absorbent drug core surrounded by an electrosprayed 
superhydrophobic protective coating that limits drug release in the absence of tensile 
strain. Coating thickness and applied tensile strain control release of chemotherapeutic 
cisplatin and enzyme β-galactosidase, as measured by atomic absorption and UV-Visible 
spectrophotometry, respectively, with preserved in vitro activity. Such mechanically-
responsive drug delivery devices, when coupled to existing dynamic mechanical forces in 
the body or integrated with mechanical medical devices, such as stents, will provide local 
controlled dosing. 
3.2 Introduction 
Mechanically-responsive biomaterials are key components in drug delivery 
devices,68,200 tissue engineering scaffolds,168,193 and sensors.113,201 The abundance of 
mechanical cues present within the body or applied externally to the body can serve as 
functional dynamic triggers.54,200,202 For drug delivery applications, these 
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mechanoresponsive devices provide spatiotemporal control over release of an active 
agent in response to compression,99,103,104 tension,123,141 or shear.146,148,152,203  
In contrast, conventional polymeric drug delivery systems offer continuous 
release due to passive diffusion, hydration, or polymer degradation with control over the 
release profile based on both polymer and agent composition, structure, molecular weight, 
hydrophobicity, and/or charge as well as their interplay. Mechanoresponsive polymeric 
drug delivery systems provide an additional feature—active control via a mechanical 
stimulus. Of the agents delivered in the clinic, small molecules and proteins are the 
mainstay but each possesses specific delivery challenges. For example, water-soluble 
small molecules embedded in polymer systems typically have low encapsulation 
efficiency and require targeted or triggered delivery to effectively localize the drug 
payload, due to diffuse biodistribution and/or fast clearance.204–206 Alternatively, the 
delivery of proteins suffers from similar obstacles, as biologically-sensitive molecules are 
prone to denaturization and aggregation with low bioavailability.207–209 Therefore, 
strategies to minimize the initial release, or trigger release on demand, as well as to 
modulate the release rate are of significant clinical interest.  
To address these challenges and increase the portfolio of drug delivery strategies 
available, we are investigating multi-layered mechanoresponsive drug delivery systems, 
where the agent is loaded in a hydrophilic core and shielded by a protective 
superhydrophobic barrier from the surrounding milieu.141 Release of the agent occurs 
upon the application of tensile strain through the formation of macroscopic cracks on the 
barrier layer that facilitate device wetting. Herein, we report the fabrication and 
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performance of devices with varied superhydrophobic coating thicknesses (100, 200, and 
350 µm) on a hydrophilic core substrate. The core substrate is amenable to solvent or 
aqueous loading of agents such that small molecules (dye, cisplatin) or proteins (β-
galactosidase) are efficiently encapsulated. Application of tensile strains modulates agent 
release through strain magnitude, barrier coating thickness, and the nature of the 
entrapped agent. Biological function is preserved after release, as evident by the 
continued activity of β-galactosidase towards its substrate, and cytotoxicity of the 
released chemotherapeutic cisplatin to cancer cells in vitro.  
3.3 Materials and methods 
Superhydrophobic materials, defined as having an advancing water contact angle 
greater than 150°,210–212 have been successfully incorporated in drug delivery systems.134 
These systems demonstrate entrapped air stability over weeks to months, and are thus 
robust barriers against release in the absence of mechanical stimuli. Utilizing this strategy, 
we fabricated mechanoresponsive systems (Figure 16) composed of an inner hydrophilic 
polyester cellulose drug core that wets immediately with water (Figure 16c, water contact 
angle = 0°) and outer superhydrophobic polymeric coatings of varying thicknesses. Both 
the low surface energy of the coating composition, consisting of biocompatible213,214 and 
biodegradable polymers poly(caprolactone) [PCL, Mw = 45 kDa] and poly(glycerol 
monostearate carbonate-co-caprolactone)186,188 [PGC-C18, Mw = 140 kDa], and the high 
surface roughness via electrospraying (Figure 16a),215 results in superhydrophobic 
coatings. Coatings of 100 µm, 200 µm, and 350 µm were electrosprayed onto the 
cellulose polyester core (Figure 16b), rendering the polymeric multi-layer structure 
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superhydrophobic (Figure 16c-d) by increasing electrospraying time (10 w/v% 1:1 PGC-
C18:PCL blend in chloroform, 2 mL/hour at 20-25 kV). A representative SEM image of 
the 350 µm coating shows surfaces composed of 2-7 µm interconnected particles with an 
advancing water contact angle of 167° (Figure 16d). A cross-sectional SEM image of the 
composite is available in Figure 17c. 100 µm and 200 µm coatings exhibit similar 
morphology and measured contact angles. Based on previous mechanical analysis,141 the 
mismatch under tension between the electrosprayed coating and the drug-loaded core 
propagates parallel crack patterns perpendicular to the direction of applied strain, 
resulting in strain-dependent release while maintaining a robust barrier in the absence of 
tension. 
Polymer synthesis: Poly(glycerol carbonate-co-ε-caprolactone), the precursor to 
poly(glycerol monostearate carbonate-co-caprolactone), was prepared as previously 
described and characterized.188  
Device fabrication: Solutions of dye (50 µL), β-galactosidase (100 µL of 2 mg mL−1 in 
0.3 M trehalose), and cisplatin (50 µL of 25 mg mL−1 anhydrous dimethylformamide) 
were loaded onto the cellulose and polyester blended mesh, followed by air-drying for 24 
hours. Loaded core substrates were affixed to a rotating and translating grounded 
aluminum drum for even coating coverage. PGC-C18 and PCL (1:1) was dissolved in 
chloroform at 10% (w v−1) and electrosprayed (20-25 kV) at a flow rate of 2 mL hr−1 and 
tip-to-collector distance of 15 cm at 30-40% relative humidity. Cisplatin was loaded at 
2.4 wt% with 97.8 +/- 8.8% encapsulation efficiency, as previously reported.141 β-
galactosidase was loaded at 0.54 +/- 0.02 wt% with 72 +/- 4.5% encapsulation efficiency.  
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Device characterization: Water contact angles (advancing = 167°, receding = 143°) were 
measured with Kruss DSA100 goniometer. Mitutoyo 293 micrometer was used to 
determine depth of coating. Samples were imaged by scanning electron microscopy with 
Zeiss ZUPRA 40VP field emission SEM (acceleration voltage = 2 kV). Samples were 
placed on aluminum stubs with double-sided copper tape and sputtercoated with 5 nm of 
gold-palladium alloy to reduce charging.  
Tension-mediated release: Devices were glued between two pieces of foam tape (3M 
Scotch), and placed between the grips of Instron 5848 tensile tester with 100 N load cell 
and submerged in a bath of PBS with 10% v/v FBS, or RPMI cell culture media (10% v/v 
FBS, cisplatin-loaded devices) with magnetic stir bar. All devices were stretched at 7% 
strain per second until the desired strain magnitude was reached. 2 mL aliquots were 
taken from the 300 mL bath at specified timepoints. Dye concentrations were measured 
with HP 8453 UV-Visible spectrophotometer at 630 nm. Cisplatin concentrations in 
RPMI with 10% v v−1 FBS was assessed using Varian AA240Z atomic absorption 
spectrophotometer at 265.5 nm with pyrolytic carbon-coated graphite tubes and Zeeman 
background correction.  
Cell culture assays: OE33 esophageal cancer cells were seeded into 12-well plates at a 
density of 2 x 104 cells per well for 24 hours before aspiration and subsequent incubation 
of release media from cisplatin-loaded devices. After 72 hours, in vitro cell viability was 
measured using the tetrazolium-based colorimetric MTS assay with absorbance at 492 
nm with Beckman Coulter AD 340 Plate Reader.  
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β-galactosidase activity: β-galactosidase activity was measured based on the released 
enzyme’s ability to convert ortho-nitrophenyl-β-galactoside into ortho-nitrophenol, 
measured with HP 8453 UV-Visible spectrophotometer at 420 nm. Released β-
galactosidase aliquots were incubated with 5.55 mM ortho-nitrophenyl-β-galactoside in 
20 mM phosphate citrate buffer at pH 4.5. After 5 hours of incubation at 20°C the 
reaction was stopped with 200 mM borate buffer at pH 9.8.  
Statistical analysis: Dye, drug, and protein release was normalized to the release area 
(excludes area of Instron mechanical tester grips). These data are presented as mean +/- 
standard deviation (or + standard deviation for ease of visualization) with a sample size 
of at least 3. Statistical significance was determined by one-way ANOVA at each time 
point with p < 0.05.  
3.4. Results and discussion 
3.4.1 Modulation of dye release by superhydrophobic coating thickness 
As an initial proof of concept, green dye (Blue 1/ Yellow 5 (Mw Blue 1 = 0.8 kDa, 
Mw Yellow 5 = 0.5 kDa)) was used as a model hydrophilic compound and loaded into the 
cellulose polyester core. We have previously reported that composites with hydrophobic, 
but not superhydrophobic, coatings composed of only PCL resulted in rapid wetting and 
release of agents in the absence of tensile strain.141 In the absence of tensile strain, 100 
µm superhydrophobic coatings minimized release of agents, with less than 10% release 
over 2 hours, while 50 µm superhydrophobic coatings did not provide a sufficient barrier 
to agent release (Figure 18).141 With superhydrophobic coatings of 350 µm, the system 
displayed strain-dependent release at 10%, 30%, and 50% strains with significant 
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differences after 5 minutes when submerged in simulated biological fluid (PBS with 10% 
fetal bovine serum) (Figure 19a). After 1 hour, ~87%, ~44%, and ~9% of the dye had 
released at 50%, 30%, and 10% strains, respectively, as detected by UV-Visible 
spectrophotometry at 630 nm.  
Applying uniaxial tensile strain of 10% (stretched to a length 10% longer than the 
original length of the mesh), the mechanoresponsive systems exhibited greater release 
with decreasing coating thickness (Figure 19b). After 15 minutes at 10% strain, the 
devices with 100 µm coatings had significantly greater cumulative release than the 
devices with 200 µm and 350 µm coatings. Between 40 and 50 minutes, there were 
significant differences in release between the 200 µm and 350 µm coatings. After 2 
hours, ~55%, ~22%, and ~14% of the dye cumulatively released with the 100 µm, 200 
µm, and 350 µm coatings, respectively.  
According to our recent study,141 applying greater tensile strain results in the 
development of cracks, increasing in both area and number, for water to infiltrate through 
the coating and subsequently release loaded agents. In this current study, the increase in 
coating thickness yields fewer and smaller cracks at low strains (Figure 19c, 10% tensile 
strain). To overcome the hindrance of the thicker barrier, higher tensile strains must be 
applied (350 µm coating at 30% strain vs 100 µm coating at 10% strain) to achieve a 
similar release profile (no statistical difference, Figure 20a).  
However, further increasing strain causes the cracks to enlarge (Figure 19f), 
providing rapid water infiltration, and resulting in greater release compared to lower 
strains but no significant differences in release among different coating thicknesses 
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subjected to the same higher strain magnitudes. For example, at 30% strain, the release is 
slower from the thicker coating (350 µm) but there is no statistical difference in the 
release compared to the 100 µm coating (Figure 19d). Furthermore, at 50% (Figure 19e) 
and 100% strains (Figure 20b) the release is further accelerated with no statistical 
difference in the cumulative release. 
3.4.2 Modulation of cisplatin dosing with in vitro by coating thickness 
Successful demonstration of hydrophilic dye release based on strain magnitude 
and coating thickness led to the determination of release kinetics and in vitro efficacy of 
cisplatin, a hydrophilic chemotherapeutic, at 10% strain. Owing to its low molecular 
weight (0.3 kDa), the release kinetics are hypothesized to be analogous to the dye loaded 
mechanoresponsive system described above. Cisplatin was encapsulated with an 
efficiency of 97.8 +/- 8.8% and its release from the device was determined by atomic 
absorption. As shown in Figure 21a, there are significant differences in cisplatin release 
starting at 5 minutes for the 100 µm coating, compared to the 200 µm and 350 µm 
coatings. However, the release only significantly differs between the 200 µm and 350 µm 
coatings at 40 minutes and 50 minutes (at which ~44%, ~14%, and ~4% are released 
from the 100 µm, 200 µm, and 350 µm coatings, respectively). Despite these minimal 
differences in cumulative release, the amount of cisplatin delivered affects the 
corresponding viability of OE33 cells, an esophageal cancer cell line, with significant 
differences after 2 minutes and until 60 minutes between the 200 µm and 350 µm 
coatings (Figure 21b). At 40 minutes, there is still ~92% viability with the 350 µm 
coating, compared to ~53% and ~2% viability for the 200 µm and 100 µm coatings, 
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respectively, demonstrating control over dosing kinetically and by coating thickness in 
vitro.  
3.4.3 Tensile-strain modulated release of enzyme β-galactosidase with preserved activity 
Based on the dye and cisplatin release results with varied strain magnitudes and 
coating thicknesses, we determined the release kinetics for a model protein, β-
galactosidase. β-galactosidase is a 116 kDa enzyme that catalyzes the conversion of β-
galactosides into monosaccharides. To determine whether the activity of β-galactosidase 
is retained with our processing fabrication conditions, the enzymatic conversion of the 
substrate ortho-nitrophenyl-β-galactoside, a colorless compound, into β-D-galactose and 
ortho-nitrophenol, a yellow compound, was quantified by UV-Visible spectrophotometry 
at 420 nm.  
Proteins form highly organized structures from which they generate specific 
functions. Hence, the preservation of protein activity is aligned with its structural 
stability, which can be denatured through physical parameters, such as temperature, light, 
dehydration, and pH.216 To overcome this challenge, excipients, including buffering 
agents, osmolytes, carbohydrates, polymers, salts, surfactants, chelators anti-oxidants, 
and preservatives, are used to stabilize proteins.217 Specifically, trehalose is a 
disaccharide and osmolyte that has been shown to maintain protein activity especially 
during drying or lyophilization.218 With trehalose as an excipient, 72 +/- 4.5% of the 
loaded β-galactosidase remains enzymatically active (Figure 22a), as solvent exposure is 
minimized from the electrospray coating process at ambient temperatures. Therefore, 
these gentle processing conditions may also be amenable for the encapsulation and 
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delivery of other active therapeutic proteins. 
With an intermediate coating thickness of 200 µm, the mechanoresponsive system 
exhibits strain-dependent release of β-galactosidase at 0%, 50%, and 100% strain with 
significant differences in release after 5 minutes until 30 minutes (p < 0.05) (Figure 22b). 
Half of the β-galactosidase releases within 5 minutes at 100% strain, while it requires 30 
minutes to achieve the same cumulative release at 50% strain. However, due to its larger 
molecular weight compared to both the dye and cisplatin in the previous examples, the 
diffusion of β-galactosidase is slower and therefore requires a greater strain magnitude to 
trigger release (50% vs. 10%). At the intermediate 50% strain, the effects of coating 
thickness are visible: half of the β-galactosidase releases at 10 minutes, 40 minutes, and 
90 minutes with the 100 µm, 200 µm, and 350 µm coatings, respectively (Figure 22c). 
After 5 minutes, there are significant differences in release with the 350 µm coating 
compared to the 250 µm and 100 µm coatings, and after 25 minutes between the 200 µm 
and 100 µm coatings. 
3.5 Conclusion 
As proof-of-concept, we selected a hydrophilic non-elastic blend of 
polyester/cellulose for the core material. However, the electrospraying process is 
amenable to coating various substrates, ranging from aluminum foil, nitrile rubber, cotton 
fabric, and collagen.185 While the coating affords barrier properties, the choice of 
substrate determines the bulk mechanical properties and agent loadability of the 
composite. The high absorbency of the polyester/cellulose core allows facile loading of 
hydrophilic small molecules and proteins, in addition to lipophilic agents, as we have 
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previously reported.141 However, this versatile absorbance is inelastic, thus limiting 
release to non-reversible tensile strain.  
The concept of utilizing crack patterns under tensile strain has been previously 
explored for both drug delivery and tissue engineering, but our strategy differs from the 
published literature. For example Zhu et al.170 demonstrate precise control of periodic 
parallel crack patterns in polydimethylsiloxane from tensile strains of 5% to 50%, 
whereby the underlying material is exposed for template-free protein patterning. Both 
myoblasts and neuroblasts reversibly spread out and retract across fibronectin-coated 
cracks in vitro. Alternatively, Mertz et al.131 use polyelectrolyte multilayered systems that 
allow an increase in enzymatic activity of embedded alkaline phosphatase under 70% 
tensile strain. Too few polyelectrolyte layers result in permeable diffusion of enzyme 
substrate while thicker layers minimize the exposure of catalytic sites, reducing 
enzymatic activity. However, our approach differs as it releases agents rather than 
immobilizing them and exhibits a graded strain-dependent response compared to the 
switchable release from these examples. Nevertheless, the surface layers are critical to the 
architecture amongst all systems, as with oxidized PDMS coated with Pluronic in the 
former example, capping polyelectrolyte layers in the latter example, and 
superhydrophobic coatings in our mechanoresponsive system.  
In summary, applying various tensile strains triggers the release of encapsulated 
agents from multi-layered superhydrophobic composites. These composites are 
composed of an inner inelastic hydrophilic core and an outer electrosprayed 
superhydrophobic coating. The superhydrophobic coating is a barrier against water 
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infiltration, and limits the release of hydrophilic dyes, a chemotherapeutic, and a protein. 
Coating thickness and applied tensile strain magnitude control agent release. Thicker 
coatings afford slower release rates with greater overall cell viability or decreased 
enzymatic activity in vitro. However, increases in strain magnitude overcome this barrier 
dependence of the coating thickness with relatively rapid agent release. Nevertheless, the 
functionality of the agents is preserved after device loading, indicating that this mild 
fabrication approach is amenable to the encapsulation of a wide-range of agents for 
biomedical applications. For example, integration of these drug-loaded multi-layered 
superhydrophobic composites with existing medical devices that perform solely a 
mechanical function (i.e., mechanotherapy) would enhance their current capability to 
include both pharmacotherapy and mechanotherapy. 
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Table 1. Measured coating thickness of fabricated mechanoresponsive devices. 
  
Substrate 
loading 
Coating Thickness 
(100 µm) 
Coating Thickness 
(200 µm) 
Coating Thickness 
(350 µm) 
Dye 113 +/- 11 205 +/- 35 360 +/- 21 
β-galactosidase 107 +/- 9 187 +/- 20 364 +/- 30 
Cisplatin 99 +/- 6 208 +/- 9 358 +/- 24 
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Figure 16. Fabrication method and characterization of superhydrophobic 
mechanoresponsive systems. a) The release agent (green) is first loaded into the mesh 
core and then electrosprayed with a mixture of PCL and PGC-C18 (yellow box). b) 
Various coating thicknesses of 100 µm, 200 µm, and 350 µm were fabricated (cross-
sectional views shown). Characterization of c) hydrophilic core and d) superhydrophobic 
coatings with SEM (left; scale bars = 100 µm and 10 µm, respectively) and advancing 
water contact angle measurements (right). Figure not drawn to scale. 
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Figure 17. Scanning electron microscope images of mechanoresponsive system with A) 
core, B) coating, and C) composite with 100 µm coating. Scale bars = 100 µm, 10 µm, 
and 100 µm respectively.  
  
		
77 
 
 
Figure 18. Release kinetics of dye in the absence of tensile strain  (0%) with 100 µm 
superhydrophobic coating (N = 3, error bars = +/- SD) and 50 µm superhydrophobic 
coating (N = 1).  
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Figure 19. Release kinetics of model hydrophilic dye from superhydrophobic 
mechanoresponsive systems  with a) 350 µm coating with various tensile strains, and 
varying coating thickness at tensile strains of b) 10% with c) corresponding photographs 
of coating cracks (top: 100 µm coating, bottom: 350 µm coating), d) 30%, and e) 50% 
with f) corresponding photographs of coating cracks (top: 100 µm coating, bottom: 350 
µm coating). Error bars denote + SD, * denote p < 0.05, N = 3, scale bar = 0.5 cm. 
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Figure 20. Release kinetics of dye from superhydrophobic coatings. a) Similar release 
profiles of 100 µm coating at 10% strain and 350 µm coating at 30% strain. b) Release 
kinetics of dye from superhydrophobic coatings of 100 µm and 350 µm at 100% tensile 
strain. Error bars denote + SD, N = 3.  
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Figure 21. Drug release profile. a) Cumulative cisplatin release at 10% strain with 
varying coating thicknesses and b) corresponding in vitro viability of OE33, an 
esophageal cancer cell line. Error bars denote +/- SD, * denote p < 0.05, and N = 3.  
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Figure 22. Encapsulation and release of β-galactosidase. a) Preservation of β-
galactosidase activity with and without trehalose excipient before and after encapsulation, 
b) tensile strain-dependent release of enzyme β-galactosidase, and c) β-galactosidase 
release with varying superhydrophobic coating thickness. Error bars denote +/- SD, * 
denote p < 0.05, N = 3 
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CHAPTER 4: Sequential delivery via geometrically localized cracks under tensile 
strain 
 
4.1 Abstract 
Regiments encompassing multiple therapeutics are necessary to treat advanced 
diseases because of the multiple complex pathways present. Thus, the need to provide 
spatiotemporal control over the sequential delivery of multiple agents is present. Herein, 
we report the selective release via mechanical stimuli from geometrically-enhanced 
mechanoresponsive systems (GEMS). By concentrating stress factors based on substrate 
geometry, the sequential release of two different dyes is controlled by the magnitude of 
applied tensile strain. 
4.2 Introduction 
Complex pathophysiological diseases and processes, such as cancer,219,220 wound 
healing,221–224 and neurological disorders,225–227 involve multiple pathways. Therefore, the 
combination of multiple therapeutics, each targeting different pathways, are more 
effective in reducing side effects, increasing bioavailability, and limiting drug resistance. 
However, the need for these therapies differ at various stages of these complex diseases 
and processes.228,229 In response, stimuli-activated systems are being developed to 
provide spatiotemporal control over sequential release.230,231  
Current reports of stimuli-responsive sequential delivery systems utilize layered 
and/or particulate systems that actively release upon changes in pH, temperature, light, 
magnetic field, redox potential or the combination of these stimuli.230–232 However, our 
macroscopic approach differs, using distinct core substrate geometries to selectively 
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trigger release with a mechanical stimulus. Given the dynamic nature of the human body 
and the increasing use of tension-driven medical devices (i.e., stents,233–236 balloon 
catheters235,237) to serve as functional mechanical triggers,200,238 we are investigating 
mechanically-activated composites to control release. Herein, we report the selective 
sequential release of two different hydrophilic dyes from these Geometrically Enhanced 
Mechanoresponsive Systems (GEMS).   
Previously we reported the use of crack propagation patterns on superhydrophobic 
composites to provide graded release based on the magnitude of applied tensile strain.141 
In the absence of mechanical stimuli, the outer electrosprayed superhydrophobic 
coating185 is a barrier, limiting water infiltration into the hydrophilic agent-loaded 
polyester/cellulose core. Increasing tensile strain causes periodic parallel crack patterns in 
the coating to form perpendicular to the direction of applied strain due to a mechanical 
mismatch between the coating and core material. These cracks then allow water 
penetration into the core, solubilizing and releasing the loaded agent in a strain-dependent 
manner. Therefore, controlling these crack patterns would provide selective control over 
release.  
The inherent randomness associated with cracks makes precise control of their 
patterns challenging but key reports demonstrate the regulation of crack propagation. 
Nam et al.239 control spontaneous crack patterns (straight, oscillatory, stitchlike) with 
silicon nitride (Si3N4) thin films deposited on silicon substrates with various 
crystallographic orientations, initiated by micro-notches on the substrate. Moreover, Kim 
et al.240 use V-notches to control crack periodicity on thin surface layers of either 
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oxidized polydimethylsiloxane (PDMS) or gold on PDMS substrate under low tensile 
strains (6%-30%).  
4.3 Materials and methods 
To localize release, GEMS are designed to geometrically concentrate stress, thus 
selectively inducing crack patterns in pre-designated areas of the composite. Stress, 
defined as the normal force per area (Equation 4), is magnified by decreasing the cross-
sectional area. Therefore, we hypothesize that the selective release from 
superhydrophobic composites will be achieved by the incorporation of a wide notch, 
where stress is locally increased under mechanical stimulus due to the decrease in cross-
sectional area. The notch provides a pre-designated area for localized crack patterns to 
develop in the coating, resulting in the selective release of the first agent when low tensile 
strains are applied to the notched composite. Applying higher tensile strains then triggers 
the release of the second agent from outside the notched area.  𝜎 = 	 YZD$G[DGC  (Equation 4) 
As proof of concept, we first fabricated dye-loaded non-notched and notched 
composites for ease of visualization. The non-notched composites are composed of a 
hydrophilic cellulose/ polyester core with dimensions of 2 cm x 4.2 cm (Figure 23a). To 
fabricate the notched samples, two parallel notches, 0.5 cm x 2 cm, were introduced, thus 
decreasing the cross-sectional area of the center by two-fold (Figure 23b). In order to 
evaluate the selective release of agents, the centers of both the non-notched and notched 
composites were loaded with red dye (Red 40 and Red 3), followed by blue dye (Blue 1) 
in the corresponding non-notched areas. These core substrates were subsequently 
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electrosprayed with 100 µm thick 1:1 mixture of biocompatible241 and biodegradable 
polymers, poly(ε-caprolactone) (PCL, 45 kDa) and poly(glycerol monostearate 
carbonate-co-ε-caprolactone)188 (PGC-C18, 140 kDa) (10 wt/v% in chloroform, 15 cm 
tip-to-collector distance, 2 mL/hr, 20-25 kV). 
4.4 Results and discussion 
4.4.1 Selective sequential release of agents by crack pattern localization 
To demonstrate localization of cracks in the superhydrophobic coating, 30% 
tensile strain is first applied to the composites, followed by 60% tensile strain (Figure 
24). With the non-notched composite, there is no statistically significant difference in 
release between the red and blue dyes at both 30% and 60% strains, although both 
increases in strain magnitude expedite the release of red and blue dyes. However, with 
the incorporation of the notched geometry in the composite, there is a statistically 
significant increase in the release of red dye, loaded in the pre-designated notched area, 
compared to blue dye at 30% strain, after 2 minutes of applying the tensile trigger (Figure 
24a). Further increasing tensile strain to 60% triggers the release of the blue dye, loaded 
outside the notched area, thus demonstrating selective sequential release of multiple 
agents. Video images in Figure 24b confirm the localization of these crack patterns with 
more cracks forming in the notched area of the composite at both 30% and 60% tensile 
strains compared to non-notched composites.  
4.4.2 Induction of crack patterns by stress concentration factors 
Stress is indirectly correlated with cross-sectional area (Equation 4). The two-fold 
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reduction in cross-sectional area from the notched portion of the composite results in a 
two-fold stress concentration. Therefore, the release of these agents from the notched 
composite demonstrate that a two-fold increase in stress is sufficient to provide selective 
crack localization and sequential agent release.  
Alternative methods to further concentrate stress include changing the notch 
geometry to a lower radius of curvature or greater notch depth.242,243 However, the 
increase in stress also affects the strain at the yield point of the core substrate. Non-
notched core substrates withstand tensile strains >120%141 but notched samples yield at 
lower strains (~65-70% strain), in agreement with the calculated two-fold increase in 
stress. Video images in Figure 24b visualize the yield differences of the two composites 
at the same strain. Thus, the introduction of notches in the geometrically-enhanced 
mechanoresponsive system enhances release selectivity but also compromises the overall 
mechanical strength of the composite.  
4.5 Conclusion 
In summary, we report the selective and sequential release of two different dyes 
from geometrically-enhanced mechanoresponsive systems controlled by the magnitude of 
applied tensile strain. Changing the geometry of the core substrate concentrates stresses 
to localize crack patterns to pre-designated areas in the superhydrophobic coating, which 
is otherwise a barrier to release. Importantly, the selective release of multiple agents is 
critical to the treatment of complex pathophysiological diseases, where spatiotemporal 
delivery is necessary to target multiple disease pathways. 
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Figure 23. Schemes and photographs of geometrically-enhanced mechanoresponsive 
system with a) non-notched and b) notched geometries, delineating release of two 
different agents. Scale bar = 1 cm.  
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Figure 24. Release kinetics from GEMS composites. a) Sequential release of dye at 30% 
and 60% tensile strains between non-notched and notched composites, error bars denote 
+ SD, * denotes p < 0.05. b) Localization of crack patterns under tensile strain, scale bar 
= 1 cm.   
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CHAPTER 5: Cycle-mediated delivery from elastomeric superhydrophobic systems 
capable of multiple dosing 
 
5.1 Abstract 
The human body exhibits and experiences many reversible cyclic processes. 
Herein, we report the design and fabrication of a composite delivery system that controls 
the pulsatile release of hydrophilic small molecules in response to such processes, 
providing cycle-mediated release when coupled with commercial balloon catheters. The 
system design entails a mechanoresponsive composite, composed of a hydrophobic 
electrospun polyurethane core exhibiting reversible elastomeric mechanical properties, 
surrounded by electrosprayed superhydrophobic coatings that minimize release in the 
absence of mechanical stimuli. Optimization of release kinetics demonstrates delivery of 
five equivalent doses, mediated by number of applied tensile cycles. Current drug-eluting 
balloon catheters only deliver hydrophobic agents and cannot be used to treat more than 
one stenosed lesion. To address these limitations, we report a pulsatile elastomeric drug 
delivery system that doses in response to the number of applied cycles. The 
mechanoresponsive composite is integrated with existing balloon catheters to control 
delivery of hydrophilic agents, such as dexamethasone sodium phosphate, to multiple 
vessel sites ex vivo, utilizing the inherent inflation and deflation of the catheter to trigger 
release. 
5.2 Introduction 
The overarching goal of drug delivery is to deliver therapeutics that maximize 
efficacy at the target site while minimizing off-target side effects. Conventional 
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polymeric delivery systems achieve continuous delivery through passive diffusion or 
polymer degradation, but sustained delivery is not optimal for all diseases. For example, 
variable pulsatile dosing is desired for vaccines,244–248 antibiotic therapy,249–251 and 
diseases with symptomatic diurnal onset (bronchial asthma, myocardial infarction, angina 
pectoris, rheumatic disease, ulcer, diabetes, hypercholesterolemia, hypertension),252,253 
requiring dosing at specified intervals. While some of these pulsatile systems are 
engineered to release at pre-determined intervals, stimuli-responsive systems offer 
additional temporal control, triggering release in response to changes in physiological or 
externally-applied stimuli.249,254–256  
Specifically, mechanically-activated systems are adept to the dynamics of the 
human body.68,200 Existing systems respond to compressive,99,101,103,106,108,257 
tensile,122,130,141,258 and shear forces.147,150,152,259 For example, Lee et al.103 reported the 
release of vascular endothelial growth factor from alginate hydrogels with repeated 10% 
and 25% compressive strain cycles, and demonstrated increased granulation tissue 
thickness and greater vascularization in treated mice. Alternatively, Di et al.123 devised a 
cyclic-tension responsive system that releases drug from microparticles embedded onto 
an elastomeric substrate. The blood glucose levels in streptozotocin-induced diabetic 
mice were reduced after applying 10 cycles at 50% strain to the system, demonstrating 
delivery of active insulin in vivo.  
For this mechanically-activated system, cyclic tension is an ideal stimulus for 
controlling release given the increasing use of well-characterized tension-driven medical 
devices in the clinic.238 Integration with such devices as balloon catheters,235,237 stents,233–
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236 or tissue expanders260–262 provides precise and reproducible forces for the delivery of 
multiple site-specific pulses of drug. Accounting for the reversibility of these expansile 
medical devices (i.e., inflation and deflation), the mechanically-activated composite 
system is designed with an elastomeric drug core, and coated with a superhydrophobic 
barrier coating that limits release in the absence of mechanical stimulus (Figure 25a). 
This cycle-dependent system exudes agent from the core upon unloading due to the 
relaxation of the core fibers, thus providing dosing based on repeated stretches. Herein, 
we report the device fabrication and subsequent optimization of the release kinetics from 
the composite, as well as the multi-dose delivery to ex vivo vessels after integration with 
a commercial balloon catheter.  
5.3 Materials and methods 
The mechanoresponsive composites are composed of a hydrophobic electrospun 
polyurethane core, which exhibits reversible elastomeric mechanical properties, and 
surrounded by electrosprayed superhydrophobic coatings (Figure 25a). The elastomeric 
core withstands the repeated loading and unloading of reversible medical devices (e.g., 
inflation and deflation of balloon catheters235,237), while the coating is a robust barrier 
against release in the absence of mechanical stimuli. Specifically, the elastomeric core is 
composed of a porous electrospun polyurethane mesh (SelectophoreTM polyurethane, 
12.5 w/v% in hexafluoroisopropanol (HFIP), 10 cm tip-to-collector distance, 10-15 kV, 
advancing contact angle = 146 +/- 4.6°) to increase the surface area available for agent 
adsorption (Figure 25c). SelectophoreTM, an aliphatic medical grade polyurethane, is 
selected as the core substrate due to its biocompatibility263,264 and high extensibility 
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(withstands tensile strains of more than 400%) with good reversibility (low hysteresis, 
minimal energy dissipation) at tensile strains up to 200% (Figure 25d). The 
biocompatible213 and biodegradable superhydrophobic coating (advancing contact angle 
= 167°) is composed of a 1:1 blend of poly(caprolactone) (PCL) and poly(glycerol 
monostearate carbonate-co-caprolactone)188 (PGC-C18) (5 w/v% in HFIP, 2 mL/hour at 
15 cm tip-to-collector distance with 20-25 kV), and prepared by electrospraying to 
produce highly textured surfaces of 2-7 µm interconnected particles215. 
We utilized superhydrophobic materials, defined as having an advancing water 
contact angle greater than 150°, because they form robust barriers against release in the 
absence of mechanical stimulus with non-wetting over weeks to months.134,184 In our 
recent works,141,265 we designed a superhydrophobic composite with a non-elastomeric 
absorbent hydrophilic polyester/ cellulose  core substrate that releases both hydrophobic 
and hydrophilic agents in a manner controlled by the magnitude of applied tensile strain 
(0% to 100%).  
Polymer synthesis: Poly(glycerol carbonate-co-ε-caprolactone), the precursor to 
poly(glycerol monostearate carbonate-co-caprolactone), was prepared as previously 
described and characterized.188 The Tin(II) catalyzed (0.002 eq) polymerization of 
monomers ε-caprolactone and 5-benzyloxy-1,3-dioxan-2-one 4:1 (mol) was conducted at 
140°C for 18 hours over nitrogen. Further deprotection by hydrogenolysis with palladium 
at 50 psi and stearic acid grafting via DCC coupling yielded poly(glycerol monostearate 
carbonate-co-ε-caprolactone) (PGC-C18, 1:4 comonomer ratio, Mw = 140 kDa, PDI = 
1.5) after repeated precipitations in cold methanol. 
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Electrospun meshes: Polycaprolactone (PCL) and polyurethane (PU) core substrates were 
fabricated by electrospinning. Polycaprolactone was dissolved in 20% (w v−1) solvent 
mixture of 5:1 chloroform: methanol. Polyurethane had limited solubility in chloroform 
and was thus dissolved in 12.5% (w v−1) hexafluoroisopropanol (HFIP). The solutions 
were loaded into a glass syringe and placed on a syringe pump with a flow rate of 10 
mL/hr for PCL and 5 mL/hr for PU at 10-15 kV with 10 cm tip-to-collector distance. The 
meshes were peeled off the underlying aluminum foil and cut to the desired dimensions.   
Device fabrication: Solutions of dye (50 µL), fluorescein (25 µL of 750 µg mL−1 of 
water), and dexamethasone sodium phosphate (25 µL of 50 mg mL−1 of water) were 
loaded onto the 50 mm x 30 mm mesh core, followed by air-drying for 24 hours. Loaded 
core substrates were affixed to a rotating and translating grounded aluminum drum for 
even coating coverage. PGC-C18 and PCL (1:1) was dissolved in HFIP at 5% (w v−1) and 
electrosprayed (20-25 kV) at a flow rate of 2 mL hr−1 and tip-to-collector distance of 15 
cm at 30-40% relative humidity. After coating one side and allowing to dry overnight, the 
subsequent sides were electrosprayed using the same conditions.  
Characterization & Instrumentation: Contact angle measurements (apparent, advancing, 
and receding) were conducted with deionized water on a Kruss DSA100 goniometer. 
Samples for scanning electron microscopy (SEM) were mounted on aluminum sample 
stubs with double-sided copper tape and sputtercoated with 5 nm of gold-palladium alloy 
to reduce charging. Samples were imaged with Zeiss SUPRA 40VP field emission SEM 
with an acceleration voltage of 2 kV, and particle size was analyzed with ImageJ 
(National Institutes of Health). Mechanical (tensile) measurements were obtained using 
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an Instron 5848 Microtester with a 100N load cell.  
Tension-mediated release: Devices were glued between two pieces of foam tape (3M 
Scotch), and placed between the grips of Instron 5848 tensile tester with 100 N load cell 
and submerged in a bath of PBS with 10% v/v FBS with magnetic stir bar. 2 mL aliquots 
were taken from the 300 mL bath at specified timepoints. Dye concentrations were 
measured with HP 8453 UV-Visible spectrophotometer at 630 nm.  
Statistical analysis: Dye and drug release was normalized to the release area (excludes 
area of Instron mechanical tester grips). This data is presented as mean +/- standard 
deviation (or + standard deviation for ease of visualization) with a sample size of at least 
3. Statistical significance was determined by one-way ANOVA at each time point with p 
< 0.05.  
µCT analysis: Microcomputed tomography studies were performed by submerging 
devices in a solution (80 mgI/mL) of iodixanol (GE Healthcare) for 5 minutes. While 
submerged, devices were elongated to a strain magnitude of 1.0. Water infiltration (i.e., 
contrast agent solution) was measured using a Scanco Medical µCT40 imaging system as 
previously described,141 using an isotropic voxel resolution of 36 µm3, 70 kVP tube 
voltage, 114 µA current, and 300 ms integration time. Image slices were converted into 
the standard image format (DICOM) using proprietary software from Scanco Medical. 
Data were reconstructed and analyzed using a commercial image processing software 
(AnalyzeTM, Mayo Clinic). In Figures 26a and 26b, the µCT images of the polyurethane 
composites with superhydrophobic coatings in air and submerged in contrast agent are 
presented. In air, there is uptake of contrast agent when the substrate is loaded or 
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stretched, with a decrease in hydration after unloading or unstretching, as visualized by 
the decrease in attenuation. Note that due to the superhydrophobic coating, the non-
stretched composite in air would provide minimal signal as there would be minimal water 
or contrast agent infiltration, in agreement with other similar superhydrophobic 
systems.178,184 Polyurethane substrates without superhydrophobic coatings exhibit an 
increase in hydration without mechanical stimulus in Figures 26c and 26d.  
Balloon catheter integration: Admiral Xtreme balloon catheters (130 cm length, 4 mm 
balloon, 40 mm balloon length) were purchased through Medtronic. The tip of the 
balloon catheter was immobilized on a 2 mm brass rod and rotated to provide even 
coverage while electrospinning. Then electrospun mesh was trimmed to the balloon area 
and loaded with fluorescein or dexamethasone sodium phosphate by directly pipetting 
solutions onto the mesh. After 24 hours of air drying, the balloon catheter was re-
immobilized onto the brass rod for electrospraying.  
Ex vivo expansions: For dexamethasone sodium phosphate expansions, 5 mm ex vivo 
segments of young rabbit aorta (Pel-Freez) were tied to barbed polypropylene fittings. 7 
Fr Input introducer sheaths (Medtronic) were inserted into Tygon PVC Clear Tubing and 
fitted with ex vivo rabbit segments (Figure 27). Following insertion of a guidewire, the 
balloon catheters were introduced through the introducer sheath to reach the target vessel 
segment and inflated to the nominal pressure of 8 atm with an EncoreTM Inflator (Boston 
Scientific) for the specified time. Tissue samples were subsequently homogenized and 
purified by Sep-Pak C18 cartridge (Waters). Dexamethasone sodium phosphate was 
quantified by high performance liquid chromatography (HP 1100 HPLC-DAD) with 50% 
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methanol and 50% water with Hamilton PRP-C18 column at 254 nm.  
5.4 Results and discussion 
5.4.1 Effect of varying core hydrophobicity and elasticity on dye release 
The composite modularity of the system allows facile determination of how 
varying core hydrophobicity affects release kinetics. We fabricated composites with 
various fibrous core substrates loaded with Blue 1 dye and covered them by 
electrospraying with 1:1 PCL:PGC-C18 superhydrophobic coating, and applied 100% 
tensile strain in a bath of PBS and 10% v/v FBS. In Figure 28a, the non-elastic 
hydrophilic polyester/ cellulose core (PE/C, Figure 28b, contact angle = 0°, purple) 
exhibits rapid dye efflux upon mechanical application as cracks form in the 
superhydrophobic barrier due to a mechanical mismatch between the coating and core 
substrates. Water easily infiltrates through the cracks into the agent-loaded core, resulting 
in dye solubilization and diffusion. In contrast, both the non-elastic and elastic 
hydrophobic cores (Figure 28b), composed of electrospun polycaprolactone (PCL, 
contact angle = 132°, blue) and electrospun polyurethane (PU, contact angle = 146°, red), 
respectively, exhibit significantly decreased dye release compared to the hydrophilic 
PE/C substrate after 2 minutes as water infiltration into the core is slowed by the increase 
in core hydrophobicity.  
An additional advantage of elastomeric substrates over non-elastic substrates is 
the ability to undergo dynamic loading (increase in strain) and unloading (decrease in 
strain). Applying sinusoidal cyclic tension from 0% to 100% strain (Cyclic PU, Figure 
28a, green, 1 cycle per minute) significantly expedites dye release after 2 minutes due to 
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greater dye efflux upon unloading. Video analysis confirms these results, demonstrating 
periodic crack formation of the coating but minimal dye release upon loading of the 
polyurethane composite (Figure 28c). This process increases the total volume of the core, 
resulting in air influx from the superhydrophobic coating as well as water influx from the 
surrounding media. Nevertheless, because there is minimal release of the hydrophilic dye, 
an interpretation consistent with our data suggests there is minimal water efflux. The 
water penetration is further confirmed by contrast-enhanced microcomputed tomography 
(µCT), where the composites are imaged before and after stretching in an aqueous 
solution of PBS and iodixanol, an anionic iodinated contrast agent (Figure 26). In the 
absence of mechanical stimulus, the composites exhibit high air attenuation as the 
superhydrophobic coating maintains a barrier to water infiltration and upon loading, there 
is contrast agent attenuation of the core, attributed to water penetration. However, dye 
rapidly effluxes from the polyurethane composite upon unloading (Figure 28d). As strain 
is decreased, the entrapped water and dissolved dye exude out of the substrate due to 
decreasing volume and relaxation of the fibers. By µCT, this process results in a decrease 
in attenuation due to contrast agent efflux, confirming that unloading of the composite 
contributes to greater agent release than loading to create a cycle-dependent system.  
5.4.2 Cycle-mediated dye release by various mechanical strain parameters 
Next, the effect of varying applied minimum and maximum strains, as well as 
strain amplitudes on dye release kinetics is investigated because cyclic loading allows 
repeated deformations of these elastic mechanoresponsive composites. With the goal of 
multiple dosing, the release kinetics are optimized to deliver similar doses by changing 
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each mechanical parameter while applying sinusoidal cyclic tension on the composite at 5 
cycles per minute in PBS with 10% v/v FBS (to simulate physiological conditions). First, 
the maximum strain applied on the system is held constant at 100%, and the minimum 
strain is varied. In Figure 29a, cycling the composite between both 100% strain and 0%, 
or 100% strain and -25% strain results in significantly faster release after 2 minutes and 5 
minutes, respectively, because these low minimum strain values allow the fibers within 
the electrospun core to relax and exude dye. At minimum strain magnitudes of 25% and 
50%, however, the system is continuously under tension and therefore less dye is exuded 
during cycling. Next, the effect of varying the applied maximum tensile strain on the 
system is determined while maintaining a minimum strain value of 0%. In Figure 29b, 
there are no statistical differences in release from the composite when the maximum 
strain applied is 50%, 100%, or 200% strain, suggesting that the full relaxation of the 
system is a strong determining criterion to expedite release. Finally, the effect of 
maintaining a constant strain amplitude of 100% on the system is tested by varying both 
minimum and maximum strains: 50% to -50% strain, 100% to 0% strain, 125% to 25% 
strain, and 200% to 100% strain (Figure 29c). In agreement with the previous data, when 
the composites are cycled between both 50% to -50% strain and 100% to 0% strain, dye 
rapidly releases after 2 minutes compared to cycling between 125% to 25% strain, in 
which the system is continually under tension. However, when the system is cycled 
between 200% and 100% strains, dye release is expedited even though the system 
remains under tension, demonstrating that increasing the maximum strain value can 
overcome the hindrance of release from the system under tension. 
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5.4.3 Optimization of dye release to deliver multiple doses 
Mechanistically, fiber relaxation of the core substrate is necessary to expedite 
release. However, when applying constant cycles to the system, linear dye release 
kinetics are not obtained. Thus, in order to achieve the goal of delivering multiple doses 
(i.e., the delivery of at least two or three similar concentrations) by cycling, we further 
investigated the effects of applying other mechanical parameters, specifically cycle 
number and cycle frequency, on the system (Figure 30a). Moreover, the robustness of the 
system is tested via step-wise release, distinguishing between the dye release kinetics 
attributed to mechanical triggers under cyclic tension and baseline dye diffusion in the 
absence of mechanical stimulus in between triggers. Furthermore, release is evaluated 
with cyclic loading between 200% and 0% strains because commercial balloon catheters 
typically undergo radial expansions up to 150% to 200% strains and because release 
kinetics between 100% and 0% strains, and 200% and 0% strains described above (Figure 
29b) do not statistically differ.  
In the first rendition, the cycles are applied to the system at constant intervals of 1 
cycle within 12 seconds, and 15 minutes at 0% strain in between each trigger set. 
However, the amount of dye released within each set decreases upon successive triggers 
(Figure 30b, blue). To further enhance release from subsequent triggers, both the number 
of cycles and the frequency of these cycles applied on the composite at each trigger are 
increased. Amongst all systems, approximately 10% of the loaded dye is released from 
the first trigger, which applies 1 cycle within 12 seconds (Figure 30b). By increasing the 
number of cycles applied at each trigger, approximately 10-15% of dye is consistently 
		
100 
released with no significant differences, demonstrating the ability to deliver multiple 
equivalent doses across five trigger sets (Figure 30b, green). However, further increasing 
the frequency of these cycles applied on the system hastens dye release, such that release 
is initially expedited but is later hindered by the decrease of available agent, thus 
resulting in statistically significant reduction in concentration change (Figure 30b, red). 
Nevertheless, step-wise pulsatile release is achieved with minimal dye diffusion in the 
absence of mechanical stimulus in between each trigger (Figure 30c).  
5.4.4 System integration with balloon catheter for multiple dosing to ex vivo tissue  
Many medical devices have a mechanical function, applying an external force on 
surrounding tissue. For example, both balloon catheters and stents are used to open 
various strictures in the body, where local delivery of anti-proliferative agents prevent 
occlusions from reoccurring.266,267 A system that integrates with these well-characterized 
devices would synergistically provide an effective delivery strategy using the inherent 
mechanics of the device.  
Specifically, balloon catheters undergo both inflation and deflation, typically 
experiencing 150% to 200% strain increases when inflated—well within the extensibility 
of our system. Thus, we integrated our system with commercial balloon catheters as a 
sheath surrounding the outer perimeter of the balloon. The 100 µm thick sheath is directly 
electrospun onto the deflated balloon, trimmed with glued edges, and loaded with either 
fluorescein (as a model hydrophilic drug for visualization) or dexamethasone sodium 
phosphate, an anti-inflammatory glucocorticosteroid.  Atherosclerosis is an inflammatory 
disease and thus anti-inflammatory agents are effective treatments.268 After air drying, the 
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superhydrophobic barrier coating is electrosprayed over the sheath, forming a protective 
barrier against release (Figure 31a). The mechanoresponsive balloon catheter is then 
inserted into an ex vivo rabbit abdominal artery and three sequential triggers, with 
increasing inflation cycles (1 inflation for 60 seconds, 2 inflations for 30 seconds each, 
and 4 inflations for 15 seconds each) are applied as the catheter advances the length of 
the artery. Under UV light, the delivery of fluorescein is visible across these three 
triggers (Figure 31b).  
The localized delivery of dexamethasone 21-disodium phosphate to ex vivo rabbit 
aorta segments is demonstrated after loading the drug into the integrated 
mechanoresponsive system. Using the same cycle triggers as the fluorescein-loaded 
devices (1 inflation for 60 seconds, 2 inflations for 30 seconds, and 4 inflations for 15 
seconds), the delivery of dexamethasone from the integrated system to ex vivo rabbit 
aorta segments does not significantly differ amongst the first two triggers with the 
delivery of ~30% of the loaded drug at each expanded vessel segment (Figure 31c). 
Nevertheless, the triggered delivery of dexamethasone at these segments is significantly 
greater than in vessel segments where the integrated balloon catheter was not expanded, 
as quantified by HPLC from tissue extracts (Figure 31c). However, the dexamethasone 
delivery from the first two triggers is significantly greater than the third and last trigger, 
as most of the loaded dexamethasone had released and <10% of drug was recovered from 
the integrated balloon catheter system after completion of the three trigger sets (Figure 
31c). Each of these three triggers delivers an efficacious dose of dexamethasone to these 
vessel segments with more than 20 ng of dexamethasone per milligram of tissue,269 
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accomplishing multiple dosing with the integrated balloon catheter system. Studies are 
ongoing to extend dosing to further delivery sites, refine the release profile to provide 
more uniform doses, and characterize the dependence of release based on loaded agent 
physicochemical characteristics. 
5.5 Conclusion 
In summary, this pulsatile elastomeric drug delivery system mediates dosing by 
the number of applied tensile cycles. The composite design entails a hydrophobic 
polyurethane core, to impart reversible elastomeric mechanical properties, and a 
superhydrophobic coating sheath that minimizes release in the absence of mechanical 
stimuli. Together, the composite provides cycle-mediated release with efflux of agent 
from the core upon cyclic unloading. The dye release kinetics from the composites vary 
with minimum and maximum cyclic strain, cyclic strain amplitude, cycle frequency, and 
cycle number. Upon optimization, five multiple equivalent doses of dye are achieved by 
applying increasing number of cycles while maintaining cycle frequency. When 
integrated with a commercial balloon catheter as a sheath with loaded dexamethasone 
sodium phosphate, balloon inflation and deflation affords drug release to multiple ex vivo 
vessel sites along the catheter track. Importantly, this design also enables the retention 
and delivery of a hydrophilic drug using a balloon catheter – a first as current commercial 
balloon catheters coated with hydrophobic agents readily experience high drug loss after 
insertion. The development of this cycle-mediated system furthers the field of 
mechanoresponsive systems through the delivery of agents under both uniaxial and radial 
tensile cycling. When coupled with current intravascular drug delivery devices, the 
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capability to perform multi-dose drug delivery in response to corresponding cycle 
number will advance the clinical field, providing known controlled administered doses to 
treat multiple diseased sites with a single intravascular device. 
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Figure 25. Characterization of the layered mechanoresponsive composite.  (a) Schematic 
representing the various layers, composed of (b) superhydrophobic electrosprayed 
coating (light yellow, scale bar = 10 µm), and (c) hydrophobic electrospun polyurethane 
drug core (scale bar = 10 µm). (d) The electrospun polyurethane core withstands 
extension up to 450% tensile strain until breakage (blue) with minimal hysteresis upon 
cycling between 0% and 200% strain (red).  
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Figure 26. µCT images of polyurethane composites with and without superhydrophobic 
coatings. a) Series of µCT images of superhydrophobic polyurethane composites in both 
air and submerged in contrast agent and its b) quantification. c) Series of µCT images of 
polyurethane mesh without superhydrophobic coatings in air and submerged in contrast 
agent and its d) quantification.   
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Figure 27. Experimental setup of ex vivo expansions. a) Schematic of inserted balloon 
catheter and trajectory to ex vivo delivery. b) Photograph of set up, scale bar = 1 cm. c) 
Photograph of barbed fittings and ex vivo rabbit segments, scale bar = 1 cm.   
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Figure 28. Effect of varying core hydrophobicity and elasticity. (a) Differences in dye 
release kinetics between a hydrophilic polyester and cellulose core (PE/C), hydrophobic 
electrospun polycaprolactone core (PCL), and hydrophobic electrospun polyurethane 
core with one-time loading (non-cyclic PU) and with cyclic loading (cyclic PU) from 0% 
to 100% strain. N = 3, error bars denote + SD, * denotes p < 0.05 for both PE/C and 
Cyclic PU from PCL or non-cyclic PU. b) Water contact angle measurements and SEM 
images of core substrates, scale bars = 100 µm, 10 µm, and 10 µm for PE/C core, and 
PCL and PU cores, respectively. PU core with superhydrophobic coating undergoing c) 
loading to 100% strain, and d) unloading to 0% strain, resulting in dye efflux. Scale bar = 
0.5 cm.  
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Figure 29. Comparison of release kinetics from reversible superhydrophobic 
mechanoresponsive systems at (a) various minimum strains, (b) various maximum 
strains, and (c) constant strain magnitudes. Error bars denote + SD, N = 3, * denotes p < 
0.05 [in (a) between 100%, 0% or 100%, -25% and both 100%, 25% and 100%, 50%; 
and in (c) between 125%, 25% and all other conditions, and 50%, -50% and 200%, 
100%].  
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Figure 30. Step-wise release  using a) various triggers, demonstrating b) different doses, 
and c) cumulative release in response to triggers, N ≥ 3, * denotes p < 0.05, ND denotes p 
> 0.05, error bars represent +/- SD.  
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Figure 31. Device integration and multidose delivery. a) Photograph of integrated 
mechanoresponsive sheath surrounding commercial balloon catheter, scale bar = 1 cm. b) 
Photograph under UV light of three sequential deliveries of fluorescein in ex vivo rabbit 
abdominal artery from balloon catheter, scale bar = 1 cm. c) Three sequential deliveries 
of dexamethasone sodium phosphate from multidose balloon catheter, * denotes p < 0.05, 
ND denotes p > 0.05.   
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CHAPTER 6: Multidose balloon catheter for the treatment of peripheral artery 
disease 
 
6.1 Introduction 
Cardiovascular disease is the leading cause of death for both men and women, 
responsible for 1 in 4 deaths in the US.270 The atherosclerotic narrowing of the arteries 
from plaque buildup can affect both the coronary arteries (17.6M patients271) and the 
peripheral arteries (8.5M patients271,272), resulting in decreased blood flow to the heart, 
legs, thighs, feet, and/or arms. Peripheral artery disease (PAD) is a subclassification of 
cardiovascular disease, excluding intracranial and coronary vessels, and the third leading 
cause of cardiovascular-related deaths, after heart attack and stroke.273 PAD is often 
asymptomatic at the onset, but develops into intermittent symptoms, such as pain and 
discomfort in the arms, thighs, or buttocks, to life-threatening consequences, such as non-
healing wounds or ulcers, gangrene, and amputation. Medical complications from 
cardiovascular disease exacerbate the costs of treatment, projected to contribute $818B in 
direct medical costs and $276B in indirect costs as the prevalence increases to 40.5% of 
the US population by 2030.274 Given the high incidence of cardiovascular disease, the 
proposed balloon catheter system would provide a less invasive surgical option to restore 
arterial blood flow and effectively prevent restenosis by delivering multiple doses of anti-
proliferative medication to small, complex, or multiple vessels. 
6.2 Endovascular treatments 
While medication and lifestyle changes are the first line treatments for 
cardiovascular disease, surgery is necessary as the disease progresses. Severely clogged 
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arterial segments are either locally treated by endovascular interventions or by surgery 
(Figure 32).275–277 Currently, nearly 400K patients in the US278–280 with multiple stenosed 
vessels or complex blocked vessels undergo invasive artery bypass surgery, where either 
a prosthetic graft or a vein from the leg is used to divert blood flow from the diseased 
artery.  
In contrast, endovascular interventions offer lower risk and minimally invasive 
options, and account for 1M procedures each year in the US.278 Endovascular 
interventions include balloon angioplasty, stent implantation, and atherectomy, which all 
mechanically re-vascularize clogged arterial segments. Atherectomy and balloon 
angioplasty are short-term procedures, where plaque is cut from the arterial walls or 
pushed to the arterial walls, respectively.281,282 Balloon angioplasty, also known as 
percutaneous transluminal angioplasty (PTA), is the current endovascular standard of 
care, where a balloon catheter is inflated for ~1 minute to restore blood flow, but results 
in 40-50% restenosis rates after 12 months, and thus requires additional interventions.283  
Alternatively, stents are long-term implants that overcome the elastic recoil from 
balloon inflation that may lead to restenosis. However, bare metal stents (BMS) have also 
resulted in late fibrosis leading to restenosis, thrombosis, and/or delayed healing with up 
to 40% in-stent restenosis in the femoropopliteal arteries after 12 months of 
implantation.284,285 Moreover, specifically in PAD, stents have performed poorly 
compared to cardiac stents due to higher vessel curvature, greater interaction with 
external forces (from musculature or pulsatile blood flow), and higher degree of stretch 
and injury in smaller vessels, resulting in stent fractures and/or restenosis.286–288 In 
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addition, as long-term implants, concerns of eliciting an inflammatory foreign body 
response remain. While recent developments of drug-eluting stents have reduced 
restenosis rates with the inclusion of anti-proliferative compounds, such as paclitaxel, to 
limit cellular ingrowth,289 drug delivery from these stents is heterogeneous and 
ineffective as drug is solely incorporated in the struts (15-30% of total area290,291). 
Furthermore, the presence of anti-proliferative agents may also interfere with re-
endothelialization of the vessel lumen that can lead to potential thrombosis, necessitating 
constant anti-platelet therapy. 
6.3 Drug-coated balloon catheters 
Drug-coated balloon catheters (DCBs) are advantageous over stents as short-term 
implants (decreased inflammatory response) with greater flexibility and more 
homogenous drug coverage to treat hard-to-access lesions (below the knee). Drug-coated 
balloon catheters are inserted through an introducer sheath into the systemic circulation 
and advanced over a guidewire to the lesion site, ideally within 30 seconds. Then the 
balloon is inflated to its nominal pressure (6-10 atm) with a saline or saline/contrast agent 
mixture for 1 minute. This short time frame represents the window of opportunity to 
deliver the necessary anti-proliferative agent for enduring restenotic effects (~2 years). 
Prolonged inflation time results in greater drug delivery but increases the risk of vessel 
injury.292–294 Minimizing off-target drug elution prior to reaching target lesion, optimizing 
drug transfer efficiency, and stabilizing the drug coating are effective strategies to 
maximize anti-proliferative potential.  
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6.4 Paclitaxel characteristics 
While the primary function of the balloon catheter remains to mechanically open 
the vessel to restore blood flow, drug-coated balloons secondarily reduce the proliferative 
response associated with restenosis. Specifically, paclitaxel is an ideal drug candidate due 
to its lipophilicity and short absorption time as well as the prolonged duration of its anti-
proliferative effect. Current drug-eluting stents utilize a handful of anti-proliferative 
agents (zotarolimus, sirolimus/rapamycin, everolimus),267 but studies incorporating these 
agents on drug-coated balloon catheters have not had as profound of an effect on 
inhibiting neointimal proliferation as paclitaxel, which stabilizes microtubules to arrest 
treated cells in the G2/M phase of mitosis. For example, although both paclitaxel and 
rapamycin localize to the tunica intima and the adventitia (Figure 33a), rapamycin does 
not penetrate as deep into arterial tissue as paclitaxel.295 This limitation, together with the 
greater efficacy of paclitaxel at lower concentrations and its persistence in the vessel 
wall, has contributed to the exclusive incorporation of paclitaxel in drug-eluting balloon 
catheters. Based on in vitro studies, approximately 1-2 ng/g of paclitaxel in tissue is 
sufficient to inhibit smooth muscle cell proliferation with 0.4 ng/g concentrations 
inhibiting smooth muscle cell migration.289,296 
Paclitaxel crystallinity further contributes to arterial uptake and retention in tissue. 
Granada et al.297 demonstrate similar initial uptake of crystalline and amorphous 
iopromide-paclitaxel formulations in rabbit abdominal arteries but greater retention with 
the crystalline formulation after 28 days (9.2% of initial levels compared to 0.04%) 
(Figure 33b). Specifically, after 28 days, the tissue drug levels of the crystalline 
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formulation were similar to that of a paclitaxel drug-eluting stent (PES, Figure 33b). This 
data, along with the partition of paclitaxel into deeper arterial tissue are hypothesized to 
contribute to the prolonged presence of therapeutic drug levels.298 
6.5 Drug-coated Balloon Catheters in the Clinic 
Currently, there are three single use drug-coated balloon catheters approved by 
the FDA for the treatment of de novo peripheral artery disease (Table 2, Figure 34): 
Lutonix 035,292,299 IN.PACT Admiral,300 and Stellarex. Each differs in its excipient 
formulation and crystalline morphology (Figure 35) to effectively deliver paclitaxel to the 
target lesion. Balloon catheters are composed of hydrophobic polymers, polyethylene 
terephthalate, polyamide (nylon), or poly(ether-block-amide), to provide high burst 
pressure with low profile.301 Current balloon catheters can withstand inflation pressures 
of 12-20 atm before bursting.  
Balloon catheters only loaded with paclitaxel have not shown to be as efficacious 
as those formulated with excipients or additives that enhance paclitaxel solubility and aid 
in partitioning to the vessel wall. One of the first drug-eluting balloon catheters, 
PaccocathTM, is formulated with iopromide and paclitaxel to reduce neointimal 
proliferation.302–305 Iopromide is a contrast agent that acts as a hydrophilic spacer to 
facilitate drug desorption from the balloon surface. Initially, the coating was formed by 
dipping, resulting in uneven coverage to balloon folds. However, microsyringe 
application is currently used to provide precise loading and coating homogeneity.306  
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6.5.1 Lutonix 035 
The first DCB for treating PAD was approved by the FDA in 2014. CR Bard/ 
BD’s Lutonix 035 includes a polysorbate/sorbitol coating excipient to deliver paclitaxel 
(2 µg/mm2). Polysorbate, or Tween, is a non-ionic emulsifier (PEGylated sorbitan, 
esterified with fatty acids) while sorbitol is a sugar alcohol. These amphiphilic excipients 
help evenly distribute microcrystalline paclitaxel during the coating process and facilitate 
drug-tissue transfer.307 
Pre-clinical porcine studies in the superficial femoral artery (internal/ external 
femoral arteries) demonstrated an initial arterial concentration of 58.8 µg/g of paclitaxel 1 
hour after expansion with exponential decay to 300 ng/g at 30 days and 91 ng/g after 180 
days.292,299 Short advancement times (30 seconds vs 180 seconds), prolonged balloon 
inflation times (30 seconds vs 3 minute), and greater balloon inflation pressure (6 atm vs 
12 and 18 atm) increased tissue drug levels post-deployment. Nevertheless, longer transit 
times, shortened balloon inflation time, and low balloon inflation pressures still resulted 
in therapeutic levels (Figure 36).292 Increasing dosing (2 overlapping balloon catheters 
with 4 µg/mm2 coating vs 1 balloon catheter with 2 µg/mm2 coating) resulted in dose 
dependent smooth muscle cell loss and greater collagen deposition with no detectable off-
target toxicity.292  
Clinically, the LEVANT 1, LEVANT 2 and its post-hoc subgroup analysis 
evaluated the efficacy of the Lutonix 035. The LEVANT 1 (101 patients) was the first-in-
human study for the Lutonix 035 for occlusive femoropopliteal artery disease, 
demonstrating a 58% reduction in late lumen loss compared to non-drug eluting balloon 
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catheters after 6 months. After 24 months, the drug eluting balloon catheter experienced 
only 39% major adverse events, compared to 46% for the PTA control group.308 In the 
LEVANT 2 (476 patients) study of obstructive de novo or non-stented restenotic lesions 
in native femoropopliteal arteries, the Lutonix 035 demonstrated overall fewer freedom 
from safety events (perioperative deaths, limb amputations, limb interventions, and limb-
related deaths) than standard PTA with superior primary patency (absence of target lesion 
restenosis, freedom from target lesion revascularization) after 1 year. However, there was 
greater—but not significantly greater—freedom from target lesion revascularization 
(TLR) in procedures using the Lutonix 035 compared to standard PTA.309,310 Hence, a 
post-hoc subgroup analysis of LEVANT 2 trial, focused on the 126 patients enrolled at 
German institutions, revealed high target lesion restenosis (96% vs 82% for PTA control) 
after 1 year. The difference between the German subgroup compared to the other US or 
European subgroups was attributed to geographical and regional differences in procedural 
variables, including higher inflation pressures (9.0 vs 7.7 atm), shorter balloon inflation 
period (130 seconds vs 167 seconds), and lower stenosis diameter post-inflation (19% vs 
22%).311 Following the commercial release of Lutonix 035, a Global SFA Registry (691 
patients, 38 centers, 10 countries) demonstrated freedom from target lesion 
revascularization and safety outcomes of 93.4% and 86.8%, respectively after 1 year, and 
90.3% and 86.7%, respectively after 2 years—all of which were higher but presumably 
more accurate rates than the LEVANT 2 clinical trial.312  
Most recently, CR Bard is ongoing acquisition by Becton Dickinson (BD, April 
2017) and also received FDA premarket approval for the use of Lutonix 035 in treating 
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dysfunctional arteriovenous fistulae, where the arteriovenous walls thicken due to 
repeated hemodialysis access in end-stage renal disease.313–315  
6.5.2 IN.PACT Admiral 
In 2015, shortly after the FDA approval of the Lutonix 035, Medtronic’s 
IN.PACT Admiral received its FDA approval for PAD treatment, utilizing a urea 
excipient to deliver paclitaxel at 3.5 – 4 µg/mm2.316–319 Similar to iopromide, urea is a 
hydrophilic excipient used to facilitate paclitaxel desorption. Urea is a natural protein 
degradation product and present in human serum at 100-500 mg/L. Coatings of 1-9 
µg/mm2 were efficacious and well-tolerated.320 In the IN.PACT SFA clinical trial (331 
patients), the IN.PACT Admiral DCB demonstrated greater primary patency (freedom 
from clinically-driven target lesion revascularization) after 1 year (82.2%, compared to 
52.4% for standard PTA), and greater freedom from clinically-driven target lesion 
revascularization within 12 months (97.6%, compared to 79.4% for standard PTA) in de 
novo and non-stented restenotic lesions in the SFA and proximal popliteal arteries.321 
After 2 years (Figure 37), the primary patency decreased to 78.9% and freedom from 
TLR was 90.9%, but these rates were still statistically greater than the PTA control 
(50.1% and 71.7%, respectively).318  
The IN.PACT Global study (1500+ patients) assessed the rates of adverse events 
with the IN.PACT Admiral, including subgroup analysis on in-stent restenosis, long 
lesion imaging, and chronic total occlusion.300 This lead to the follow-up clinical study, 
FAIR (119 patients), on the efficacy of the IN.PACT Admiral for in-stent restenosis in 
the superficial femoral artery.322 After 6 months, there was a lower recurrent restenosis 
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rate with DCB (15.4%), compared to standard PTA (44.7%). After 12 months, restenosis 
rates increased but remained significantly less in DCB (29.5%), compared to standard 
PTA (62.5%). Freedom from TLR after 12 months was also significantly greater in the 
DCB group (90.8%) compared to 52.6% for the control PTA group. These results led to 
the FDA approval for the IN.PACT Admiral to treat in-stent restenosis in peripheral 
arteries—the first and only drug-coated balloon catheter approved for this indication. 
Additional small clinical trials have evaluated the efficacy of the IN.PACT Admiral in 
conjunction with bare metal stents (DCB + BMS, or PTA + BMS, DEBATE-SFA),323 
drug eluting stent (Zilver PTX),324 and atherectomy.325,326 Medtronic recently (Jan 2017) 
obtained FDA approval for an investigational device exception (IDE) to initiate a study in 
the US, in conjunction with European clinical studies,327,328 to evaluate the efficacy of the 
IN.PACT Admiral for treating arteriovenous fistulas. 
6.5.3 Stellarex 
Most recently, Philips/Spectranetics’s Stellarex balloon catheter (2 µg/mm2 
paclitaxel loading) was approved by the FDA and incorporates a 8kD poly(ethylene 
glycol) (PEG) excipient for release of paclitaxel. PEG is a non-fouling hydrophilic 
polymer. The coating is composed of both amorphous and crystalline paclitaxel for 
greater transfer and retention, respectively. The PEG formulation is claimed to allow 
greater coating flexibility as the catheter advances.  
In the ILLUMENATE First in Human clinical trial (50 patients), the efficacy of 
the Stellarex balloon catheter was demonstrated with 80.3% primary patency after 2 years 
and freedom from target lesion revascularization at 85.8% after 2 years.329 The European 
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and US ILLUMENATE clinical trials (222 patients and 300 patients, respectively) 
demonstrated primary patency (89% compared to 65% for standard PTA, and 82.3% 
compared to 70.9% for standard PTA, respectively) and low rates of target lesion 
revascularization (5.9% compared 16.7% for standard PTA, and 7.9% compared to 
16.8% for standard PTA, respectively) with Stellarex after 1 year.330,331  
6.6 Current DCB issues 
Pre-clinically, efficacy and safety studies of new drug-coated balloon catheter 
designs are conducted in healthy, young pigs. This animal model may not translate 
clinically for older, diseased patients with less compliant and more calcified arteries. 
Moreover, within pre-clinical animal models, there may also be unavoidable data scatter. 
In a retrospective study, Speck et al. 2016306 analyzed 15 porcine studies over 9 years, 
comparing late lumen loss between their negative control (uncoated balloon catheters, 
222 pigs collective total) and their positive control (PaccocathTM-coated balloon 
catheters, 133 pigs collective total) (Figure 38). Two of these 13 studies indicated no 
statistical difference between these control groups, and in 4 of the studies, the individual 
negative control groups significantly differed from the rest of the negative control groups.  
Despite the success of these commercial DCBs clinically, it is estimated that 
current drug-eluting balloon catheters lose 70% of their drug systemically before 
reaching their target lesion and 10% of their drug downstream, with 10% remaining on 
the balloon catheter after inflation, resulting in only 10% transfer to the target vessel 
wall.306,332 However, even with the high dosage lost due to systemic circulation, toxicity 
is expected to be minimal. Compared to a maximum dose of 7 mg on an IN.PACT 
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Admiral drug-eluting balloon catheter (7 mm diameter x 80 mm length), a regular 
paclitaxel dose for chemotherapy is ~300 mg and a dosage less than 70 mg would not 
cause myelosuppression or peripheral neuropathy.333  
Current concerns plaguing balloon catheters include downstream particulates, 
especially with crystalline formulations. Specifically, particulates in the capillary beds of 
the lower extremities (coronary band) and in downstream skeletal muscle may result in 
embolism or vascular tissue reaction to paclitaxel.334 Crystalline paclitaxel, present on all 
three FDA-approved commercial DCBs, is currently the favored drug coating 
formulation due to longer persistence in arterial tissue as an effective drug reservoir 
within vessel wall layers.306,335 However, less brittle coatings may result in fewer 
particulates lost downstream.298,336  
Furthermore, physician handling of the device prior to deployment can lead to 
unintended exposure of paclitaxel as well as decreased availability for the patient’s target 
lesion.292 Accounting for this issue, the Lutonix 035 comes with a peelable, as opposed to 
a slidable, protective sheath to minimize shear stresses that may result in drug loss during 
handling. 
6.7 Multi-dose balloon catheter 
Current drug-eluting balloon catheters are limited by their: 1) single use / site 
application; 2) no control of dose; and 3) drug loss during insertion and advancement to 
stenosis site. Therefore, a balloon catheter that delivers multiple drug doses will provide a 
less invasive surgical option for patients with disease in smaller, complex, or multiple 
vessels.  
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As a unique improved approach, the proposed multi-dose balloon catheter 
represents a paradigm shift in the management of treatment of peripheral artery disease. 
The innovative materials and treatment concept:  
• Integrates with current balloon catheters  
• Provides cycle-dependent multi-dose release (3+ doses) 
• Treats multiple complex vessels, long lesions, and smaller blocked vessels 
• Offers more even drug distribution, compared to drug-eluting stents (only 15-30% 
coverage) 
• Minimizes drug loss during advancement to lesion site (current balloon catheters 
elute drug during insertion with recommended vessel advancement time of 30 
seconds) 
• Reduces surgery time and need for invasive surgery  
• Eases manufacturing by reducing number of catheter sizes (different balloon 
diameters will be produced but different catheter lengths will no longer be 
necessary) 
6.8 Balloon catheter integration and fabrication 
The mechanoresponsive system is integrated with commercial balloon catheters 
as a sheath surrounding the outer perimeter of the balloon. SelectophoreTM and 
HydroThaneTM polyurethanes, as biocompatible elastic substrates, were dissolved in 
hexafluoroisopropanol at 12.5 w/v%. The polyurethane mesh was directly electrospun 
onto the balloon catheter (Admiral Xtreme (Figure 39a, 4 mm diameter, 40 mm length)) 
at 5 mL/hr, 12-15 kV, 10-12 cm tip-to-collector distance for 2 minutes. The mesh was 
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allowed to dry overnight, trimmed (Figure 39b), and a 3 mm long superelastic nitinol 
wire (0.008’’ diameter) was inserted into the mesh to allow for radiopaque visualization. 
Finally, the mesh was glued at the edges with cyanoacrylate surgical adhesive and New 
Skin liquid bandage to minimize delamination under shear and provide a smooth profile 
for insertion, respectively (Figure 39c). Paclitaxel was dissolved at 50 mg/mL acetone 
and 2 mg (x3) was loaded onto the mesh by pipetting. The crystallinity of the paclitaxel 
and paclitaxel urea formulations are visualized by polarizing microscopy (Figure 40). The 
elastic polyurethane mesh expands with the inflation of the balloon, demonstrating 
minimal interference with primary mechanical function (Figure 39d).  
6.9 Ex vivo flow model 
Young rabbit aorta segments were purchased from Pel-Freeze and attached to 
polypropylene barbed fittings (McMaster-Carr). These were attached to Tygon tubing 
(5/16" ID, 7/8" OD, Saint-Gobain). The intake tubing was attached to a recirculating bath 
of PBS + 10% FBS with a peristaltic pump (40 mL/min, Fisher Scientific™ Variable-
Flow Peristaltic Pumps) to mimic blood flow (Figure 41). An introducer sheath was 
inserted into the Tygon tubing and guidewire was advanced prior to insertion of the drug-
coated balloon catheters. The balloons were inflated for 60 seconds, then deflated. The 
aorta segment was removed and replaced with another vessel segment-fitting, and the 
balloon was inflated for 60 seconds. The second aorta segment was removed and replaced 
with the last aorta-fitting, and the balloon was inflated for an additional 60 seconds. 
Finally, the drug from the balloon catheter was extracted by soaking the catheter in 
3x3mL methanol over three days. Drug quantification was completed by BASi 
		
124 
(Bioanalytical Systems, Inc.) using LC/MS/MS.  
6.10 Proposed pre-clinical large animal model 
New drug-coated balloon catheter systems are typically tested pre-clinically in 
healthy porcine models (domestic pigs, 80 kg) with arterial overstretch or stent 
implantation, both of which stimulate neointimal proliferation. For the surgery, the pigs 
were sedated (Telazol IM 4-6 mg/kg), intubated and anesthesized (1-5% isoflurane). 
Blood samples are drawn from the marginal ear vein. The carotid artery was exposed 
through a cut down for the introduction of the 7 French introducer sheath. Heparin (IV, 
5000 U) was administered and angiograms were taken to image and select vessel 
diameters. Balloon catheters (commercial IN.PACT Admiral (N = 6) or the multidose 
design (N = 6)) were inserted and expanded (1.1-1.2x overexpansion) in the iliac or 
femoral arteries, for a total of four sites. Three of these four sites were expanded 
sequentially: 1x60 seconds, 1x60 seconds, and 1x60 seconds. The fourth site serves as an 
expanded control with a non-drug coated balloon catheter (Figure 41). After removal of 
balloon catheter, the incision is closed with sutures (3-0 vicryl), and pigs would be 
awakened with buprenorphine (0.03-0.05 mg/kg IM). Half of the animals (N = 6) would 
be euthanized at 7 days, and the other half (N = 6) would be euthanized at 28 days.  After 
euthanasia, tissue samples would be used for histology and drug quantification.  
6.11 Conclusion 
Current drug-coated balloon catheters are single-use devices, with short 
recommended vessel advancement times due to rapid drug loss and delivers less than 
10% of the loaded paclitaxel to the target vessel site. This anti-proliferative agent must be 
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transferred to the vessel wall in less than 2 minutes for enduring restenotic effects lasting 
over 2 years. Current drug-coated balloon catheters attempt to overcome this problem by 
using different excipients (iopromide, urea, polysorbate/ sorbitol, PEG) to facilitate drug 
transfer and clinical data demonstrate the efficacy of these drug-coated balloon catheters 
over standard PTA, but drug loss remains significant (>70%). Moreover, the diffuse 
nature of peripheral artery disease with multiple diseased sites result in difficult treatment 
with traditional surgical or endovascular methods. Hence, the proposed multi-dose 
balloon catheter would transform the treatment of PAD. Utilizing the reversibility (i.e., 
inflation and deflation) of balloon catheters, we designed a tension-responsive sheath that 
surrounds the outer perimeter of the balloon catheter capable of delivering multiple doses 
of paclitaxel to diseased arteries in ex vivo and in vivo large animal studies.  
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Figure 32. Potential treatment algorithm for femoropopliteal lesions, including 
endovascular interventions. Figure adapted from Refs. [282] and [283].   
		
127 
 
Figure 33. Distribution of anti-proliferative agents in bovine and rabbit vessels. A) 
Transmural equilibrium distribution of dextran (♦), paclitaxel (□), and rapamycin (◊) in 
0.040-mm-thick bovine internal carotid tissue segments, TBC = Tissue Binding Capacity. 
B) Paclitaxel tissue levels over 28 days of amorphous paclitaxel-coated balloons (AC), 
crystalline paclitaxel-coated balloons (CC), and the Taxus stents (PES). Figure adapted 
from Refs. [300] and [302].  
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Table 2. Overview of commercial FDA-approved paclitaxel (PTX) drug-eluting balloon 
catheters and our proposed device.  
  
Balloon 
Catheter Manufacturer 
PTX 
dosage Excipients 
FDA approved 
indication 
Multi-
dosing 
capability 
IN.PACT 
Admiral Medtronic 
3.5 
µg/mm2 Urea 
De novo lesions 
In-stent restenosis û 
Lutonix 
035 CR Bard/ BD 
2 
µg/mm2 
Polysorbate 
Sorbitol 
De novo lesions 
Arteriovenous 
fistulae 
û 
Stellarex Spectranetics/ Phillips 
2 
µg/mm2 
Poly(ethylene 
glycol) De novo lesions û 
Multi-
dose  
Target:  
12 
µg/mm2 
To be 
determined  ü 
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Figure 34. Light microscopy pictures of commercial balloon catheters (a) IN.PACT 
Admiral and (b) Lutonix 035. Scale bar = 1 mm. 
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Figure 35. SEM images of DEB paclitaxel coatings with various excipients: A) 
paclitaxel-iopromide coating with macro-crystalline morphology; B) Medtronic’s 
IN.PACT Admiral balloon catheter with urea excipient that cracks and flakes off after 
hydration; C) Boston Scientific’s micro-crystalline TransPax coating with BTHC 
excipient (butyryl-tri-n-hexyl citrate). Figure adapted from Ref. [310].  
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Figure 36. Paclitaxel tissue concentrations 1 hour post-expansion of Lutonix 035 balloon. 
Effects of A) transit time and inflation time, and B) inflation pressure on tissue 
concentration 1 hour post-expansion of Lutonix 035 balloon catheter. Figure adapted 
from Ref. [268]. 
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Figure 37. Clinical results with Medtronic’s IN.PACT Admiral drug-coated balloon 
catheter. (A) Primary patency and (B) freedom from clinically driven target lesion 
revascularization compared to standard PTA. Figure adapted from Ref. [321].  
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Figure 38.  Late lumen loss in 15 studies in swine, 13 thereof in which uncoated balloons 
(Ctr.) served as negative and PaccocathTM-coated balloons (Pac.) served as positive 
control; high scatter in the control groups and low LLL in all groups treated with 
PaccocathTM. Figure adapted from Ref. [270].  
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Figure 39. Photographs of multidose balloon catheter. (a) Balloon catheter covered by 
sheath prepared via sequential (b) electrospinning and (c) electrospraying, and (d) device 
inflation. Scale bar = 1 cm. 
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Figure 40. Light microscopy images of paclitaxel-ureaunder A) non-polarizing light, and 
B) polarizing light at the polyurethane mesh-drug boundary; and paclitaxel under C) non-
polarizing light and D) polarizing light at the mesh-drug boundary. Scale bar = 200 µm. 
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Figure 41. Set up for ex vivo expansions in recirculating bath. 
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Figure 42. Fluoroscopic angiogram of consecutive balloon inflations in domestic pig.   
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CHAPTER 7: Surface tension sensor meshes for rapid alcohol quantification 
Adapted from: Surface tension sensor meshes for rapid alcohol quantification, RSC 
Advances. 2017; 7:49795-49798. 
7.1 Abstract 
A surface tension sensor detects alcohol in solution by determining the transition 
of a liquid droplet from non-wetted to wetted states. Results from testing commercial 
wines are presented along with fabrication of electrospun two-layer polymeric sensor 
arrays, which exhibit controlled wettability.  
7.2 Introduction 
Quantification of alcohol by volume (ABV) in alcoholic beverages is required for 
commercial sales and is also of significant interest for winemakers. Alcohol 
quantification is traditionally performed using densitometry, though, increasingly, high 
performance liquid chromatography (HPLC) and Fourier transform infrared spectroscopy 
(FTIR) are supplanting its use.337,338 However, these instruments are expensive and 
require trained staff, making rapid and accurate alcohol determination impractical for 
small-to-medium scale winemakers or for measurements in the cellar from fermentation 
barrels or tanks.  
Ethanol contributes the greatest reduction in surface tension of wine,339,340 
beer,341,342 and spirits.343,344 In wine, a multivariate analysis found that surface tension 
alone predicts alcohol content to the same degree as a model incorporating levels of 
protein, sugar, and tannins.340 Surface tension is the basis of alcohol determination in 
vinometers, thin tubes in which the capillary rise is measured, but these devices lack 
		
139 
accuracy when not extremely clean or when sugars are present.345 More accurate and 
repeatable surface tension measurements generally require expensive and difficult to use 
tensiometers. Here we report an alternative method using a simple surface tension sensor 
composed of an electrospun polymeric mesh on which a droplet of liquid will either 
remain ‘beaded up’ with a high contact angle or be rapidly absorbed. This difference in 
wetting state, highlighted by a color change, allows rapid, instrument-free quantification 
of alcohol content using only small volumes. 
7.3 Materials and Methods 
Mesh sensor manufacture and characterization: The poly(glycerol-co-e-caprolactone) 
(PGC-OH) and hydrophobic poly(glycerol monostearate-co-e-caprolactone) (PGC-C18) 
were synthesized as described by Wolinsky et al.,188 with MW of 54 and 39 kDa, and 
dispersities of 1.36 and 1.57, respectively. Electrospinning solutions were dissolved in 
5:1 chloroform:methanol at 150 mg/mL, and pumping through a 20 ga. blunt needle at 3 
mL/hr, while applying 12-20 kV. First the indicator solution of 5% bromocresol purple, 
5% PGC-OH and 90% PCL was electrospun for 10 minutes, then the PGC-C18 blend 
indicated in Table 3 was electrospun for the prescribed time. The aluminum collector is a 
grounded cylinder that rotates and translates to increase mesh area and uniformity. The 
meshes were characterized by SEM and contact angle measurements. 
Experimental Setup: A Nikon D3200 SLR camera with a macro lens was set on a tripod 
with mesh sensors on black cardboard for taking photographs. Using a set timer, pictures 
were obtained every 15 seconds. Several different commercial wines were used for all 
studies (Table 4). For the data presented in Figure 44, ethanol was added to commercial 
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wines to obtain an ABV% of 15.5 and 16%.  The yellow, non-wetted sensors are easily 
distinguished from the orange, wetted sensors.  
7.4 Results and Discussion 
These sensors function by exploiting the transition in wetting states of liquids near 
the critical surface tension on porous material. Contact angle is a function of surface 
hydrophobicity and air-liquid surface tension. Rough surfaces such as electrospun meshes 
exhibit exaggerated apparent contact angles when fully wetted or when partially wetted, 
as described by the Wenzel and Cassie-Baxter states, respectively.346 The partially wetted 
state accounts for the remarkable properties of superhydrophobic materials, which have 
been the subject of much research recently.134,182,347–354 The transition between these two 
wetting states occurs at a specific surface tension and triggers a large change in apparent 
contact angle, and is the basis for the mechanism of our sensors. The alcohol sensors 
(Figure 43a) are composed of a) an upper ‘responsive’ layer that allows wetting of liquids 
only below a specific surface tension, and b) a hydrophilic lower ‘indicator’ layer that 
wets completely and provides a color change from the dissolution of the incorporated 
dye, bromocresol purple. This color change is indicative of the Cassie-Baxter (non-
wetted) to Wenzel (wetted) states. An array of these sensors with responsive layers tuned 
to different critical surface energies allows the quantification of the liquid surface 
tension, and hence, the alcohol content. Wine alcohol content is strongly correlated with 
surface tension, as shown in Figure 44, and as been previously reported.340  
The sensor meshes were composed of the biocompatible and biodegradable 
polymers: poly(e-caprolactone) (PCL) (70-90 kDa), doped with varying amounts of 
		
141 
hydrophilic PGC-OH or hydrophobic PGC-C18. The bottom indicator layer (Figure 43a, 
orange) facilitates wetting as all contact angles were <90° with ethanol water solutions 
containing greater than 9% ABV. The polymer solutions for preparing the responsive 
layers (Figure 43a, grey) were between 3 and 5% PGC-C18 dissolved at 150 mg/mL, and 
were electrospun at the same time as the indicator layer for the first 30 seconds (to 
prevent delamination), then for varying times afterwards, between 5 and 15 minutes. Five 
different meshes with varying hydrophobicity were fabricated to span the relevant range. 
The detailed electrospinning parameters, and contact angles (both with water and 9% 
ethanol) are listed in Table 3. As geometry (mesh thickness, fiber diameters, porosity) and 
material hydrophobicity both influence surface energy, water and ethanol apparent 
contact angles were both measured for meshes #1-5 to resolve differences in surface 
tension. Meshes that exhibit higher contact angles (and therefore have lower critical 
surface tensions) are designed to detect higher alcohol contents.  
Surface tensions of the test wines were measured in quintuplicate by the 
Wilhelmy Plate method on a Kruss K11 tensiometer using flame-cleaned glass cover 
slips. Contact angles were recorded on video by a Kruss DSA100 goniometer using 
Laplace-Young fitting and all droplets are 3 µL at 21 - 23˚C. Model wines were 
commercial wines with labeled alcohol by volume (ABV) of 12.5 - 14.0%. Details on the 
wine types can be found in Table 4. Three µL droplets were added to meshes, and 
photographed every 15 seconds using manual settings. The time-to-wet is defined as the 
time after droplet addition to <90˚ apparent contact angle and orange color change, as 
shown in Figures 43, 45 and 46.  
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As demonstrated in Figure 43b, a clear change in wetting state is observed 
between 9.5% ABV and 10% ABV ethanol water solutions and further highlighted by a 
slight color change on Mesh #1. Figure 43c shows the results from using the mesh to 
resolve the difference between a metastable non-wetting Cassie-Baxter state to a rapidly 
wetting Wenzel state with only a 0.5% change in the alcohol content. The structure of a 
representative sensor mesh is shown in Figure 43d. The top responsive layer is of 
controlled thickness and composed of 2-3 micrometer diameter fibers with a specific 
hydrophobic PGC-C18 content, while the bottom indicator layer is composed of 
hydrophilic nanofibers with PGC-OH and bromocresol purple dye. If droplets from an 
unknown sample are placed on an array of sensors (with varying amounts of the 
hydrophobic PGC-C18 in the top responsive layer) that wet at different surface tensions, 
the alcohol content in the sample is determined, as discussed below.  
Four meshes of varying construction are wetted by wines of different alcohol 
contents, as shown in Figure 45. Mesh #3 resolves a 0.5% alcohol difference in a wine 
(Figure 45a). The combination of the three other meshes (Figure 45b) allows 
determination of alcohol content to <1% ABV between 12.5 and 15.5% ABV. The 
robustness of the system is demonstrated with non-wetted droplets remaining non-wetted 
for up to 16 minutes, allowing greater discrimination between wetted and non-wetted 
states while an accurate response can be discerned as quickly as 30 seconds. This specific 
senor array can not detect ABV below or above 12.5 and 15.5%, respectively. The alcohol 
contents shown here assume the commercially reported values are precise.  
Example photos of this visible change in wetting states on the alcohol sensor 
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meshes are shown in Figure 46. Sensor meshes with increasing hydrophobicity are wetted 
by wines of increasing alcohol contents, at which point the wine dissolves the 
bromocresol purple dye in the lower layer and turns the sensor orange. In every case the 
wetting occurred within 30 seconds, and the non-wetting droplets remained for at least 5 
minutes. This time difference is sufficient to be discerned without a timer, and the color 
change allows detection of wetting by a naked eye. Collectively using four of these 
sensors enables determination of alcohol content in an unknown wine sample with a 
droplet of wine added to each sensor and observing the color change after 30 seconds. 
Thus, an experimenter, blinded to wine type and alcohol content, used the sensor array to 
determine the ABV of the unknown wine. The sensor array correctly determined the wine 
as having an ABV between 14.0 and 15.0%. The wine was revealed to be Carol Shelton 
Old Vine Monga Zin 2014, 14.5% ABV. 
A thorough study of the effects of responsive layer thickness, fiber diameter, 
polymer blend, humidity and temperature on wetting rates is ongoing to further elucidate 
the subtle changes that give rise to the resulting mesh performances. For example, a 
14.0% ABV ethanol solution in water decreases by ~0.4 mN/m for every 3˚C increase, 
equivalent to ~0.5% ABV,343 so temperature must be accounted for or controlled in a 
final device. Additionally, proper handling is required as scratches to the surface or 
contamination will affect the performance. Electrospinning is a well-controlled, robust 
commercialized manufacturing process and as such supports the use of this fabrication 
method. We recently reported a point-of-care diagnostic sensor based on surface tension 
for fat determination in breast milk with a set of polymeric meshes with different surface 
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properties,355 and together all of these results document the generality of our approach. 
Our results also suggest that materials with high porosity and well-controlled geometry 
may exhibit similar sensitivity, therefore, encourages the investigation of additional 
fabrication methods and prepare new surface tension sensors for analysis of varied 
aqueous and non-aqueous solutions. Finally, this sensor design based on observing the 
wetting phenomena complements other visible (e.g., colorimetric) detection systems, 
from the common pregnancy test to sophisticated arrays for analyte identification using 
chemical compound arrays via molecular fingerprints.356–363  
7.5 Conclusion 
In wine, the phenolics and terpenes along with the sugars and acids define the 
character of the wine and the resulting nuances of flavors. The alcohol content in wine 
also influences the sensory profile of the wine – with flavor intensities and balance being 
greatest at specific alcohol percentages.364 Accurate determination of alcohol content is 
essential for winemakers to maximize flavors and comply with labeling requirements. 
However, the current methods for measuring alcohol content require trained personnel or 
expensive equipment, and are not amenable for easy use in the field, i.e., point-of-cask 
analogous to point-of-care365–368 for medical diagnostics. The strong correlation between 
alcohol content and surface tension enables facile and rapid quantification of alcohol 
using an array of polymeric mesh sensors with controlled wettability.  
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Figure 43. Schematic of alcohol sensor system  A) Profile of alcohol sensor with upper 
‘responsive’ layer that allows wetting at a specific surface tension and lower ‘indicator’ 
layer that facilitates wetting and provides a color change (light orange). B) 
Discrimination between a 9.5% (left) and 10% (right) ethanol water solution on Mesh #1 
(scale bar = 3 mm) with 5 µL droplets. C) The wetting response of sensor Mesh #1 can 
resolve a 0.5% ABV difference in ethanol water solutions. Wetting time was capped at 20 
minutes, error bars represent ± SD, n = 3. D) SEM image of a representative sensor mesh 
structure (scale bar = 15 µm).  
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Figure 44. The relationship between surface tension and alcohol content (ABV%) for 
commercial wines.  
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Mesh PGC-C18 (%) 
Electrospin time 
(min) 
Water Adv.     
CA  (°) 
9% Ethanol Adv. CA 
(°) 
#1 3.75 6 141.9 ± 4 131.4 ± 2.4 
#2 3.0 15 144 ± 2 135.5 ± 4 
#3 3.75 7 147 ± 1 136 ± 6 
#4 4.0 5 147.9 ± 0.4 143 ± 4 
#5 3.75 8 149 ± 6 144 ± 2.6 
Table 3. Electrospinning parameters for each sensor mesh, with advancing contact angles. 
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Vintner Type/Region/Grape Year ABV (%) 
D. Violon Côtes du Rhône 2014 12.5 
Machadinho Vinho Tinto 2014 13.0 
Old Moon Zinfandel 2013 13.5 
Casillero del Diablo Cabernet Sauvignon 2014 13.5 
Pagos de Tahola Rioja 2007 14.0 
Table 4. Wines under evaluation. 
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Figure 45. Detection of alcohol content by sensor array wetting  A) Discrimination of 
commercial wines at 13.5 and 14.0% alcohol on Mesh #3 (scale bar = 3 mm). B) The 
wetting response of four sensor meshes to alcohol content, each sensor resolving 1% 
ABV, n ≥ 3, error bars denote ± SEM. The dashed line represents 30 seconds, the time at 
which the wetted/ non-wetted response was observed. The (*) denotes a difference from 
zero, p < 0.005.  
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Figure 46. Alcohol sensors resolve 0.5% ABV differences in commercial wines.  
Droplets of 3 µL were added to each sensor. Photographs of the sensors are one minute 
after droplet addition. The non-wetting droplets remained for >5 min. 
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CHAPTER 8: Summary 
  
Mechanically-activated drug and protein delivery systems harness existing forces 
in the body to provide greater control over release. The field of mechanically-stimulated 
delivery is rapidly growing with a number of reports demonstrating the promise of 
releasing pharmaceutical/ active agents in a controlled manner. These mechano- 
responsive systems are designed to be clinically relevant through the use of physiological 
force triggers or externally applied clinical devices.  This dissertation investigates novel 
mechanoresponsive systems that respond to tensile strain or cyclic tensile loading, and 
their integration with existing medical devices.  
Chapter 1 highlights the seminal reports of mechanoresponsive systems that 
respond to compression, tension, or shear. The review focuses on current biomaterial 
compositional designs and how these structure-property relationships are utilized to 
improve upon existing biomedical applications. 
Chapter 2 first explores the use of tensile strain as a trigger to modulate release in 
superhydrophobic composites. Exploiting the mechanical differences between the 
superhydrophobic barrier coating, which inhibits water penetration, and the hydrophilic 
core substrate, coating crack patterns develop to provide strain-dependent release of a 
dye, a hydrophilic chemotherapeutic cisplatin, and a lipophilic chemotherapeutic SN-38 
with in vitro efficacy against an esophageal cancer cell line, OE33. Towards clinical 
applications, the integration with an esophageal stent locally delivers agents to ex vivo 
esophageal tissue upon stent expansion.  
In Chapters 3-4, strategies to further tune drug and protein release kinetics based 
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on coating properties are explored. Changing the thickness of the superhydrophobic 
barrier coating modulates release of active small molecules (dye, cisplatin) and protein 
(β-galactosidase) in vitro, providing an additional parameter to control release based on 
tensile strain. The selective sequential release of agents is further demonstrated with the 
Geometrically-Enhanced Mechanoresponsive System (GEMS), localizing crack patterns 
based on different geometric stress concentration factors.  
Finally, in Chapters 5-6, a hydrophobic elastomeric system is devised, creating a 
cycle-mediated composite. The pulsatile delivery of multiple doses is accomplished 
through uniaxial tensile loading and unloading, as well as radial expansion via balloon 
catheter to ex vivo rabbit blood vessels. An integrated sheath that envelops the balloon 
catheter expands the current capabilities of commercial balloon catheters with the 
potential to control delivery of anti-inflammatory or anti-proliferative agents to multiple 
sites for the treatment of peripheral artery disease.  
The development of mechanoresponsive delivery systems and combination drug-
device products will enhance existing technologies in the treatment of cardiovascular, 
musculoskeletal, and pulmonary diseases as well as cancer. Furthermore, the 
comprehensive range of specific kinetic profiles, including triggered release, pulsatile 
delivery, and the sequential delivery of multiple agents, showcases the capabilities and 
versatility of these dynamic mechanoresponsive systems to modulate release for the 
treatment of a wide-range of clinical diseases.  
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